

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER DISCHARGE DUE TO COMMUNITY-ACQUIRED PNEUMONIA IN PEOPLE AGED 65 YEARS OR MORE DURING TWO INFLUENZA SEASONS. A PROSPECTIVE STUDY.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020243
Article Type:	Research
Date Submitted by the Author:	24-Oct-2017
Complete List of Authors:	Toledo, Diana; Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica; Universitat de Barcelona, Medicina Soldevila, Núria; Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica; Universitat de Barcelona, Medicina Torner, Nuria; Agència de Salut Pública de Catalunya, Servei de Control Epidemiològic; Universitat de Barcelona, Medicina Perez, M <sup>a</sup> José; Hospital Valme, UGC Prevenció, Promoció y Vigilancia de la Salud Espejo, Elena; Hospital Universitari de Terrassa, Internal Medicine Navarro, Gemma; Hospital Parc Tauli, Egurrola, Mikel; Hospital de Galdakao Dominguez, Angela; Universitat de Barcelona, Medicina; Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Infectious diseases, Public health, Geriatric medicine
Keywords:	Community acquired pneumonia, readmission, elderly, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3 FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER DISCHARGE  
4 DUE TO COMMUNITY-ACQUIRED PNEUMONIA IN PEOPLE AGED 65 YEARS  
5 OR MORE DURING TWO INFLUENZA SEASONS. A PROSPECTIVE STUDY.  
6  
7  
8  
9

10  
11 **Authors:** Diana Toledo,<sup>1,2</sup> Núria Soldevila,<sup>1,2</sup> Núria Torner,<sup>3,2,1</sup> M<sup>a</sup> José Pérez,<sup>4</sup> Elena  
12 Espejo,<sup>5</sup> Gemma Navarro,<sup>6</sup> Mikel Egurrola,<sup>7</sup> Ángela Domínguez,<sup>2,1</sup> and the Project FIS  
13 PI12/02079 Working Group  
14  
15

16  
17  
18 <sup>1</sup> Centro de Investigación Biomédica en Red Epidemio Epidemiología y Salud Pública,  
19 Madrid, Spain  
20

21  
22 <sup>2</sup> Universitat de Barcelona, Barcelona, Spain  
23

24 <sup>3</sup> Agència de Salut Pública de Catalunya, Barcelona, Spain  
25

26 <sup>4</sup> Hospital Valme, Seville, Spain  
27

28 <sup>5</sup> Hospital de Terrassa, Terrassa, Spain  
29

30 <sup>6</sup> Corporació Sanitària i Universitaria Parc Taulí, Barcelona, Spain  
31

32 <sup>7</sup> Hospital de Galdakao, Usansolo, Spain (M Egurrola).  
33  
34  
35  
36

37 **Correspondence:**

38 Diana Toledo.

39 Universitat de Barcelona,

40 C/ Casanova, 143, 08036,

41 Barcelona, Spain.

42 Email: [diannitz@gmail.com](mailto:diannitz@gmail.com)  
43  
44  
45  
46  
47  
48  
49

50 **Word count:** 2123  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** Rehospitalization after discharge due to community-acquired pneumonia (CAP) discharge is frequent in the elderly and patients with multiple comorbidities, resulting in a clinical and economic burden. The aim of this study was to determine factors associated with 30-day readmission in patients with CAP.

**Design:** A prospective study.

**Setting:** The study was conducted in patients admitted to 20 hospitals in seven Spanish regions during two influenza seasons

**Participants:** We included patients aged  $\geq 65$  years admitted through the emergency department with a diagnosis compatible with CAP. Patients who died during the initial hospitalization and those hospitalized  $> 30$  days were excluded.

**Main outcome measures:** 30-day readmission.

**Results:** Factors associated with 30-day readmission were male sex (aOR 1.44 95% CI 1.01-2.04), living with a person aged  $< 15$  years (aOR 2.12, 95% CI 1.01-4.47), moderate-to-high degree of dependency (aOR 1.52, 95% CI 1.09-2.11), chronic respiratory failure (aOR 1.73, 95% CI 1.22-2.44), congestive heart disease (aOR 1.70, 95% CI 1.21-2.38), chronic liver disease (aOR 2.39, 95% CI 1.21-4.36) and discharge to home with home health care (aOR 5.53, 95% CI 1.67-18.30). No associations were found with pneumococcal or seasonal influenza vaccination in any of the three previous seasons.

**Conclusions:** This study shows that 11.39% of patients aged  $\geq 65$  years initially hospitalized for CAP were rehospitalized within 30 days after discharge. Rehospitalization was associated with preventable and non-preventable factors.

**Strengths and limitations of this study**

- All the information on readmission was obtained from medical records.
- The study is part of a multi-center study carried out in seven autonomous communities representing 70% of the Spanish population.
- It was not possible to collect detailed information about the readmission episode.

For peer review only

## INTRODUCTION

Community-acquired pneumonia (CAP) is a frequent, potentially serious disease in people aged  $\geq 65$  years and one of the leading causes of hospitalization and mortality worldwide in this age group,[1-4] in whom recovery from an episode of CAP is predictive of increased mortality in subsequent years.[5]

The incidence of CAP differs between European countries due to variations in age distribution, the introduction of vaccination programs and the clinical guidelines used. However, the incidence of cases and hospitalizations increases with age in all countries.[6,7] In Spain, CAP is not a notifiable disease and therefore the incidence in the population is unknown, although 2013 data also show an increase in hospitalization (394.04 per  $10^5$  in the 65-74 years age group and 2584.95 per  $10^5$  in the  $>85$  years age group).[8]

In people aged  $\geq 65$  years, full recovery after hospital discharge due to CAP is usually slow and the probability of readmission during a period of time after discharge is greater. 30 day readmission post discharge is usually used as an indicator of vulnerability.[2,10-12]

Readmission after discharge due to CAP is relatively frequent (especially in the elderly and patients with multiple comorbidities), and is often associated with a worsening of a baseline disease or the appearance of a new pathology,[13] and this becomes a significant clinical and economic burden for health systems.[2,14] Studies have explored the factors associated with readmission following hospitalization due to CAP, and have identified factors that improve the prognosis at discharge and are considered preventable, such as influenza and pneumococcal vaccination, use of hospital care protocols, discharge planning and post-discharge follow-up. Adequate discharge

1  
2  
3 planning, including patient stability and destination, has been associated with reduced  
4  
5 readmission.[15-17] However, the effect of seasonal influenza and pneumococcal  
6  
7 vaccination and the adequacy of hospital care (use of clinical guidelines and antibiotic  
8  
9 plans) may be more controversial.[18-21] The initial severity of CAP, worsening of  
10  
11 comorbidities and some individual patient characteristics have been described as non-  
12  
13 preventable factors,[15,21-25] and factors such as age, sex, socioeconomic status,  
14  
15 education and some comorbidities have been independently associated with a greater  
16  
17 likelihood of readmission.[25,26]  
18

19  
20  
21 The objective of this study was to determine the risk factors associated with 30-day  
22  
23 readmission in people aged  $\geq 65$  years initially hospitalized due to CAP.  
24

## 25 26 **MATERIALS AND METHODS**

### 27 28 **Study design**

29  
30 This study was carried out as part of a multicenter study in 20 hospitals from seven  
31  
32 Spanish regions (Andalusia, the Basque Country, Castile and Leon, Catalonia, Madrid,  
33  
34 Navarre, and Valencia Community). Patients aged  $\geq 65$  years hospitalized due to CAP in  
35  
36 the participating hospitals during the 2013–2014 and 2014–2015 influenza seasons were  
37  
38 recruited.  
39

### 40 41 **Study population**

42  
43  
44 Patients included were aged  $\geq 65$  years admitted through the emergency department to  
45  
46 any of the participating hospitals for  $\geq 24$  hours with a chest X-ray showing pulmonary  
47  
48 infiltrate compatible with pneumonia and  $\geq 1$  of the following symptoms or signs of  
49  
50 acute lower respiratory tract infection: cough, pleural chest pain, dyspnea, fever  $>38^{\circ}\text{C}$ ,  
51  
52 hypothermia  $< 35^{\circ}\text{C}$ , and abnormal auscultator respiratory sounds unexplained by other  
53  
54 causes.  
55  
56  
57

1  
2  
3 Patients who died during the initial hospitalization and patients hospitalized for > 30  
4 days were not included. Institutionalized patients, patients with nosocomial pneumonia  
5 (onset  $\geq$  48 hours after hospital admission) and those who did not provide signed  
6 informed consent were excluded.  
7  
8  
9

## 10 11 12 **Outcomes**

13  
14  
15 The dependent variable was 30-day readmission, defined as ‘hospitalization for any  
16 reason within 30 days of discharge after index admission’. Information on readmission  
17 was collected by re-review of medical records up to more than 30 days after initial  
18 discharge.  
19  
20  
21  
22

23  
24 All participating hospitals had a specifically-trained team of health professionals who  
25 used a structured questionnaire to collect information by patient interview on  
26 confirmation of the case and review of medical records.  
27  
28  
29

30  
31 Information collected included sociodemographic variables: age, sex, marital status,  
32 educational level, cohabitation; lifestyle factors: smoking status (current smoker, ex-  
33 smoker, non-smoker) and alcohol intake (> 40 g/day in men, > 20 g/day in women); the  
34 Barthel index (ranging from 0 - complete dependence - to 100 - complete independence)  
35 was used to assess the functional capacity at hospital admission.<sup>27</sup> Patients were  
36 considered vaccinated against pneumococcal disease if they had receive a dose of  
37 pneumococcal vaccine in the last 5 years and against seasonal influenza if they had  
38 received a dose of the influenza vaccination at least 14 days before symptom onset. The  
39 presence or absence of underlying diseases (chronic respiratory failure, history of  
40 pneumonia during the last two years, solid or hematologic neoplasm, diabetes mellitus,  
41 renal failure, chronic obstructive pulmonary disease (COPD), congestive heart disease,  
42 disabling neurological disease, chronic liver disease and hemoglobinopathy or anemia),  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57



1  
2  
3 prior medical utilization (number of primary care nurse visits in the last 3 months,  
4  
5 number of hospital visits in the last 3 months) and hospital care process (severity of  
6  
7 illness quantified in 5 risk classes using the Pneumonia Severity Index at admission,  
8  
9 length of stay  $\geq 8$  days and  $< 7$  days,[8] intensive care unit (ICU) admission, mechanical  
10  
11 ventilation, adequacy of antibiotic treatment plan (validated according to clinical  
12  
13 guidelines) (Yes/No) and discharge disposition (home without services, home with  
14  
15 home health care and social health centre) were collected.[16]  
16  
17  
18  
19  
20

### 21 **Statistical analysis**

22  
23 The Barthel index, a continuous variable, was dichotomized into 0-89 (moderate to high  
24  
25 degree of dependency) and  $\geq 90$  (little or no dependency).  
26  
27

28  
29 A bivariate analysis was made to compare 30-day readmission and no readmission  
30  
31 according to sociodemographic variables, lifestyle factors, the Barthel index,  
32  
33 immunizations, risk medical conditions, prior medical utilization and hospital care  
34  
35 process. Independent variables were checked for collinearity using the variance inflation  
36  
37 factor.[28]  
38  
39

40  
41 As Spanish autonomous communities have varying degrees of autonomy in organizing  
42  
43 health services, persons living in the same region tend to have similar access to health  
44  
45 care. Therefore, to estimate the crude and adjusted odds ratio (OR), we used multilevel  
46  
47 regression models that considered the outcome variable in people from the same region  
48  
49 to obtain accurate statistical estimates of predictors of 30-day readmission.[28]  
50

51  
52 Covariates were introduced into the model using a backward stepwise procedure, with a  
53  
54 cut-off point of  $p < 0.2$ .  
55  
56  
57  
58  
59  
60

1  
2  
3 The analysis was performed using the SPSS v.24 statistical package and Rv3.3.0  
4  
5 statistical software.  
6  
7

### 8 9 **Ethical approval**

10 The study was approved by the Ethics Committees of the participating hospitals.  
11  
12  
13

## 14 15 **RESULTS**

16 Overall, 1929 inpatients met all study eligibility criteria for CAP: 93 patients died  
17  
18 during the initial hospitalization and 80 were hospitalized for > 30 days. Therefore, 1756  
19  
20 CAP cases were discharged within 30 days after the initial hospitalization: of these, 200  
21  
22 (11.39%) were readmitted within 30 days after hospital discharge (Figure 1).  
23  
24  
25

26  
27 Figure 1. Flowchart of hospital readmissions  
28  
29

30 Reasons for 30-day readmission were collected in 188 cases and were unrelated to  
31  
32 pneumonia in 52.7% (99 cases-comorbidities in 80 and other causes in 19) and  
33  
34 pneumonia-related in 47.3% (80 cases).  
35  
36

37 The descriptive analysis and unadjusted associations of factors related to 30-day  
38  
39 readmission are shown in table 1. Readmission was associated with sociodemographic  
40  
41 variables (male sex, living with a person aged < 15 years vs. living alone, moderate-to-  
42  
43 high degree of dependency according to the Barthel Index), chronic respiratory failure,  
44  
45 pneumonia during the last two years, congestive heart disease, chronic liver disease,  
46  
47 mechanical ventilation, length of hospital stay  $\geq 8$  days and discharge to home with  
48  
49 home health care vs. discharge to home without services.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Distribution of 30-day readmission cases according to patient characteristics

	Readmission n=200	No Readmission n=1556	Crude OR	p value
<b>Sociodemographic</b>				
<b>Age group</b>				
65-74 y.	56 (28.0%)	501 (32.2%)	1	
75-84 y.	98 (49.0%)	729 (46.9%)	1.20 (0.85-1.70)	0.31
>84 y.	46 (23.0%)	326 (20.5%)	1.26 (0.83-1.91)	0.27
<b>Sex</b>				
Female	64 (32.0%)	622 (40.0%)	1	
Male	136 (68.0%)	934 (60.0%)	1.44 (1.05 – 1.97)	0.02
<b>Educational level</b>				
No/primary education	153 (78.1%)	1118 (72.4%)	1	
Secondary or higher	43 (21.9%)	427 (27.6%)	0.75 (0.51-1.10)	0.14
<b>Marital status</b>				
Married/Cohabiting	116 (58.0%)	912 (58.6%)	1	
Single	21 (10.5%)	107 (6.9%)	1.56 (0.94-2.59)	0.09
Widowed/divorced	63 (31.5%)	536 (34.4%)	0.93 (0.67-1.29)	0.66
<b>Cohabitants</b>				
Live alone	31 (15.5%)	289 (18.6%)	1	
Lives with cohabitant >15 y.	155 (77.5%)	1203 (77.4%)	1.20 (0.80 – 1.80)	0.39
Lives with cohabitant <15 y.	14 (7.0%)	63 (4.1%)	2.03 (1.02 – 4.04)	0.04
<b>Lifestyle factors</b>				
<b>Smoking status</b>				
Non smoker	79 (39.5%)	693 (44.5%)	1	
Smoker	16 (8.0%)	138 (8.9%)	1.04 (0.59-1.83)	0.90
Ex-smoker	105 (52.5%)	725 (46.6%)	1.28 (0.94-1.75)	0.11
<b>Alcohol intake &gt;40gr</b>				
No	197 (98.5%)	1524 (97.9%)	1	
Yes	3 (1.5%)	32 (2.1%)	1.38 (0.42-4.54)	0.60
<b>Prior utilization of resources</b>				
<b>N° of nurse visits within 90d</b>				
0-2	147 (73.5%)	1182 (76.4%)	1	
≥3	53 (26.5%)	365 (23.6%)	1.17 (0.82-1.65)	0.39
<b>N° of hospital visits within 90d</b>				
0-2	164 (82.8%)	1355 (87.6%)	1	
≥3	34 (17.2%)	192 (12.4%)	1.53 (1.02-2.31)	0.04
<b>Barthel index</b>				
Little or no dependency >90	108 (54.0%)	990 (63.6%)	1	
Moderate-to-high dependency ≤90	92 (46.0%)	566 (36.4%)	1.47 (1.08-2.01)	0.01
<b>Immunizations</b>				
<b>Influenza vaccination in any of the 3 previous seasons</b>				
No	54 (27.0%)	464 (29.8%)	1	
Yes	146 (73.0%)	1092 (70.2%)	1.16 (0.83-1.61)	0.39
<b>23-valent pneumococcal polysaccharide vaccine</b>				
No	161 (80.5%)	1281 (82.3%)	1	
Yes	39 (19.5%)	275 (17.7%)	1.11 (0.76-1.62)	0.58
<b>Risk medical conditions</b>				
<b>Chronic respiratory failure</b>				
No	136 (68.0%)	1269 (81.6%)	1	
Yes	64 (32.0%)	287 (18.4%)	2.08 (1.50 – 2.88)	<0.001
<b>Pneumonia during the last 2 years</b>				

No	146 (73.0%)	1267 (81.4%)	1	
Yes	54 (27.0%)	289 (18.6%)	1.65 (1.18 – 2.32)	0.004
<b>Any malignancy</b>				
No	161 (80.5%)	1271 (81.7%)	1	
Si	39 (19.5%)	285 (18.3%)	1.08 (0.74 – 1.58)	0.67
<b>Diabetes</b>				
No	139 (69.5%)	1023 (65.7%)	1	
Si	61 (30.5%)	533 (34.3%)	0.83 (0.60 – 1.14)	0.26
<b>Renal failure</b>				
No	151 (75.5%)	1263 (81.2%)	1	
Si	49 (24.5%)	293 (18.8%)	1.38 (0.97 – 1.96)	0.07
<b>COPD</b>				
No	128 (64.0%)	1074 (69.0%)	1	
Si	72 (36.0%)	482 (31.0%)	1.25 (0.92 – 1.70)	0.16
<b>Congestive heart disease</b>				
No	128 (64.0%)	1168 (75.1%)	1	
Si	72 (36.0%)	388 (24.9%)	1.69 (1.24 – 2.31)	0.001
<b>Chronic liver disease</b>				
No	186 (93.0%)	1504 (96.7%)	1	
Si	14 (7.0%)	52 (3.3%)	2.13 (1.15 – 3.94)	0.01
<b>Hemoglobinopathy or anemia</b>				
No	160 (80.0%)	1324 (85.1%)	1	
Si	40 (20.0%)	232 (14.9%)	1.40 (0.96 – 2.04)	0.08
<b>Disabling neurological disease</b>				
No	179 (89.5%)	1416 (91.0%)	1	
Si	21 (10.5%)	140 (9.0%)	1.17 (0.72 – 1.90)	0.52
<hr/>				
<b>Hospital process of care</b>				
<b>ICU</b>				
No	188 (94.5%)	1499 (96.9%)	1	
Si	11 (5.5%)	48 (3.1%)	1.93 (0.97 – 3.81)	0.06
<b>Mechanical ventilation</b>				
No	157 (78.5%)	1317 (84.9%)	1	
Si	43 (21.5%)	235 (15.1%)	1.50 (1.03 – 2.18)	0.03
<b>Pneumonia severity index</b>				
I-III	69 (34.7%)	645 (41.7%)	1	
IV-V	130 (65.3%)	902 (58.3%)	1.40 (1.02 – 1.92)	0.04
<b>Length of hospital stay</b>				
<8 days	80 (40.0%)	766 (49.2%)	1	
≥8 days	120 (60.0%)	790 (50.8%)	1.45 (1.05 – 2.02)	0.02
<b>Antibiotic treatment</b>				
No	97 (50.3%)	700 (46.6%)	1	
Yes	96 (49.7%)	802 (53.4%)	1.07 (0.76 – 1.50)	0.70
<b>Discharge disposition</b>				
Home without services	185 (92.5%)	1477 (94.9%)	1	
Home with home health care	9 (4.5%)	19 (1.2%)	5.05 (1.58 – 16.15)	0.01
Social health centre	6 (3.0%)	60 (3.9%)	1.23 (0.41 – 2.92)	0.63

COPD: Chronic obstructive pulmonary disease.

Table 2. Results of multilevel regression of factors associated with 30-day readmission.

	aOR	p value
<b>Sex-Male</b>	1.44 (1.01 – 2.04)	0.04
<b>Educational level</b>		
Secondary or higher	0.77 (0.53-1.13)	0.18
<b>Cohabitants</b>		
Live alone	1	
Lives with cohabitant >15 y.	1.25 (0.75 – 2.09)	0.39
Lives with cohabitant <15 y.	2.12 (1.01 – 4.47)	0.048
<b>Marital status</b>		
Married/Cohabiting	1	
Single	1.81 (1.00-3.30)	0.05
Widowed/divorced	1.07 (0.71-1.61)	0.74
<b>Nº. of hospital visits ≥3</b>	1.52 (1.00-2.32)	0.05
<b>Barthel index</b>		
Moderate-to-high dependency ≤90	1.52 (1.09-2.11)	0.01
<b>Pneumonia during the last 2 years</b>	1.34 (0.94 – 1.93)	0.11
<b>Chronic respiratory failure</b>	1.73 (1.22 – 2.44)	0.01
<b>Diabetes</b>	0.72 (0.51 – 1.01)	0.05
<b>Congestive heart disease</b>	1.70 (1.21-2.38)	0.002
<b>Chronic liver disease</b>	2.29 (1.21 – 4.36)	0.01
<b>Mechanical ventilation</b>	1.33 (0.90 – 1.97)	0.15
<b>Discharge disposition</b>		
Home without services	1	
Home with home health care	5.53 (1.67-18.30)	0.005
Social health centre	1.23 (0.51-2.97)	0.64

Factors independently associated with 30-day readmission in the multilevel analysis (Table 2) were male sex (aOR 1.44 95% CI 1.01-2.04; p=0.04), living with a person aged < 15 years (aOR 2.12, 95% CI 1.01-4.47; p=0.04), a moderate-to-high degree of dependency (aOR 1.52, 95% CI 1.09-2.11; p=0.01), chronic respiratory failure (aOR 1.73, 95% CI 1.22-2.44; p=0.01), congestive heart disease (aOR 1.70, 95% CI 1.21-2.38; p=0.002), chronic liver disease (aOR 2.39, 95% c 1.21-4.36; p=0.01) and discharge to home with home health care (aOR 5.53, 95% CI 1.67-18.30; p=0.005).

1  
2  
3 Being single and  $\geq 3$  hospital visits during the last three months were tentatively  
4 associated with readmission (aOR 1.81, 95% CI 1.00-3.30;  $p=0.05$  and aOR 1.52, 95%  
5 CI 1.00-2.32;  $p=0.05$ , respectively).  
6  
7  
8

9  
10 No associations were observed with age, pneumococcal vaccination or seasonal  
11 influenza vaccination in any of the three previous seasons, the pneumonia severity  
12 index, or any variable related to the hospital care process.  
13  
14  
15

## 16 **DISCUSSION**

17  
18  
19  
20 The overall 30-day readmission rate in our study was 11.39%. Although all participating  
21 hospitals were reference centres, readmission rates ranged from 2.5% to 14% between  
22 autonomous communities. Possible explanations include variations in the number of  
23 people assigned to each hospital and the protocols used.  
24  
25  
26  
27

28  
29  
30 Readmission rates at 30 days after discharge due to CAP in people aged  $\geq 65$  years are  
31 usually between 8% and 27%, depending on the population and country  
32 studied.[11,19,21,25,29] In Spain, national data show hospital readmissions after 30  
33 days of discharge due to CAP in adults had increased from 11.5% in 2004 to 13.5% in  
34 2013.[8]  
35  
36  
37  
38  
39

40  
41 Some of the risk factors identified have not previously been reported and their  
42 identification provides a new perspective on the risk factors involved in 30-day  
43 readmission. Our results show that non-preventable factors, specifically patient  
44 characteristics (male sex, living with a person aged  $< 15$  years, a Barthel Index  $< 90$  and  
45 some comorbidities) were significantly associated with 30-day readmission. A  
46 systematic review by Calvillo-King et al. evaluated the impact of social factors on  
47 hospital readmission after an episode of CAP, considering socio-demographic,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 socioeconomic and social environment elements, and found few studies that included  
4  
5 them.[22]  
6

7  
8 Although the influence of sex varies between studies and may be closely related to other  
9  
10 factors such as age, risk habits and some comorbidities, we found an association with  
11  
12 male sex, as did studies by Neupane et al. and Bohannon et al.[19,30]  
13

14  
15 Patients living with children aged < 15 years had a two-fold higher probability of  
16  
17 readmission than those living alone or with a partner. We found no studies that  
18  
19 investigated the type of cohabitation in this context, possibly because one factor usually  
20  
21 associated with readmission in people aged  $\geq 65$  years is living in geriatric  
22  
23 residences.[11] We also found no association with factors identified by other authors,  
24  
25 such as the educational level or the history of smoking or alcohol use.[25,31]  
26  
27

28  
29 In the studies by Neupane et al. in two Canadian cities and Adamuz et al. in a tertiary  
30  
31 hospital in Barcelona, seasonal influenza and pneumococcal vaccination were included  
32  
33 in the adjusted analysis of readmission due to CAP, but no association was  
34  
35 found.[19,23] We investigated seasonal influenza and pneumococcal vaccination in the  
36  
37 last five years but found no association in the crude or adjusted models.  
38  
39

40  
41 In our study, 52.7% of 30-day readmissions were due to causes unrelated to CAP.  
42  
43 Patients with chronic liver disease, congestive heart disease and respiratory failure had  
44  
45 higher 30-day readmission rates, findings consistent other studies showing that  
46  
47 comorbidities play an important role in the risk of readmission in patients with  
48  
49 CAP,[12,23-25] and that the reason for readmission generally differs from the initial  
50  
51 diagnosis of CAP.[10,23-26,32,33]  
52  
53

54  
55 We found an association with hospital consultations in the 90 days before admission for  
56  
57 CAP, but no association with GP and primary care nurse visits in the bivariate analysis,  
58  
59

1  
2  
3 and this variable was not included in the final model. Health care in Spain is free, which  
4 encourages patients to make multiple visits to primary care centers and/or hospitals,  
5 ensuring patient care and follow-up. Adamuz et al. and Tang et al. found an association  
6 between readmission and hospitalization in the 90 days before admission for  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

CAP.[11,23]

One preventable factor that influences CAP episodes in people aged  $\geq 65$  years is the quality of care they receive during hospitalization, while discharge planning and follow-up until recovery influence patient recovery and, therefore, readmission.[16,21,23,24]

We found, as did Dong et al.,[16] an association with discharge to home with home health care. Although other variables were studied to assess these aspects, there was no association between them and readmission.

### **Strengths and limitations**

The main strength of the study is that the information on readmission was obtained from the medical record and, therefore, was unlikely to be biased. Another strength is the prospective design, as it is part of a multi-center study carried out in seven autonomous communities representing 70% of the Spanish population.

A limitation is that it was not possible to collect patient characteristics at discharge, and therefore we cannot say whether there was instability at discharge that may have caused the readmission. Also it was not possible to collect detailed information about the readmission episode. Therefore the variable 'discharge disposition' was considered as a proxy to define instability.

### **CONCLUSIONS**

In conclusion, this study shows that 11.39% of patients aged  $\geq 65$  years hospitalized due to CAP are readmitted within 30 days after discharge and that this was associated with



1  
2  
3 male sex, living with a cohabitant aged <15 years, a moderate-to-high degree of  
4  
5 dependency, chronic respiratory failure, congestive heart disease, chronic liver disease  
6  
7 and discharge to home with home health care services.  
8  
9

10 Because social factors, in addition to post-discharge and pre-readmission clinical  
11  
12 information, may influence the prognosis, it is important they continue to be considered  
13  
14 in future research.  
15

16  
17 **Author contributions:** DT, is the guarantor of this article. DT, MJP, EE, GN, ME and  
18  
19 AD, designed the research. DT, and NS conducted the statistical analyses. DT, NT and  
20  
21 AD wrote the initial draft of the manuscript, and DT, NS, NT, MJP, EE, GN, ME and  
22  
23 AD reviewed the manuscript for accuracy and scientific content.  
24  
25

26  
27 **A funding statement:** This study was supported by the Institute of Health Carlos III  
28  
29 with the European Regional Development Fund (FEDER) (PI12/02079) and the Catalan  
30  
31 Agency for the Management of Grants for University Research (AGAUR Grant number  
32  
33 2014/ SGR 1403). The funders had no role in the study design, data collection and  
34  
35 analysis, decision to publish, or preparation of the manuscript.  
36  
37

38  
39 **Competing interests:** The authors declare no competing interests.  
40

41  
42 **Data Sharing Statement:** No additional data available.  
43

44  
45 **Acknowledgements:** The members of the Project PI12/02079 Working Group are, by  
46  
47 region: Andalusia: JM Mayoral (Servicio de Vigilancia de Andalucía), J Díaz-Borrego  
48  
49 (Servicio Andaluz de Salud), A Morillo (Hospital Universitario Virgen del Rocío), MJ  
50  
51 Pérez-Lozano (Hospital Universitario Virgen de Valme), J Gutiérrez (Hospital  
52  
53 Universitario Puerta del Mar), M Pérez-Ruiz, MA Fernández-Sierra (Complejo  
54  
55 Hospitalario Universitario de Granada). Castile and Leon: S Tamames (Dirección  
56  
57

1  
2  
3 General de Salud Pública, Investigación, Desarrollo e Innovación, Junta de Castilla y  
4 León), S Rojo-Rello (Hospital Clínico Universitario de Valladolid), R Ortiz de Lejarazu  
5 (Universidad de Valladolid), MI Fernández-Natal (Complejo Asistencial Universitario  
6 de León), T Fernández-Villa (GIIGAS-Grupo de Investigación en Interacción Gen-  
7 Ambiente y Salud, Universidad de León), A Pueyo (Hospital Universitario de Burgos),  
8 V Martín (Universidad de León; CIBERESP). Catalonia: A Vilella (Hospital Clínic), M  
9 Campins, A Antón (Hospital Universitari Vall d'Hebron; Universitat Autònoma de  
10 Barcelona), G Navarro (Corporació Sanitària i Universitaria Parc Taulí), M Riera  
11 (Hospital Universitari Mútua Terrassa), E Espejo (Hospital de Terrassa), MD Mas, R  
12 Pérez (ALTHAIA, Xarxa Hospitalaria de Manresa), JA Cayla, C Rius (Agència de Salut  
13 Pública de Barcelona; CIBERESP), P Godoy (Agència de Salut Pública de Catalunya;  
14 Institut de Recerca Biomèdica de Lleida, Universitat de Lleida; CIBERESP), N Torner  
15 (Agència de Salut Pública de Catalunya; Universitat de Barcelona; CIBERESP), C  
16 Izquierdo, R Torra (Agència de Salut Pública de Catalunya), L Force (Hospital de  
17 Mataró), A Domínguez, N Soldevila, I Crespo (Universitat de Barcelona; CIBERESP),  
18 D Toledo (Universitat de Barcelona). Valencia Community: M. Morales-Suárez-Varela  
19 (Universidad de Valencia; CIBERESP), F. Sanz (Consorci Hospital General  
20 Universitari de Valencia). Madrid: J Astray, MF Domínguez-Berjon, MA Gutiérrez, S  
21 Jiménez, E Gil, F Martín, R Génova-Maleras (Consejería de Sanidad), MC Prados, F.  
22 Enzzine de Blas, MA Salvador, S Rodríguez, M Romero (Hospital Universitario la  
23 Paz), JC Galán, E Navas, L Rodríguez (Hospital Ramón y Cajal), CJ Álvarez, E  
24 Banderas, S Fernandez (Hospital Universitario 12 de Octubre). Basque Country: M  
25 Egurrola, MJ López de Goicoechea (Hospital de Galdakao). Navarre: J Chamorro  
26 (Complejo Hospitalario de Navarra), I Casado, J Díaz-González, J Castilla (Instituto de  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Salud Pública de Navarra; Instituto de Investigación Sanitaria de Navarra; CIBERESP).  
4  
5  
6  
7

## 8 **References**

9

- 10  
11 1. Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients.  
12 *Clin Geriatr Med* 2007;23:515-34.  
13  
14  
15  
16 2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-  
17 acquired pneumonia among adults in Europe. *Thorax* 2012;67:71-9.  
18  
19  
20  
21 3. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal  
22 disease in adults. *Clin Microbiol Infect* 2012;18(Suppl5):7-14.  
23  
24  
25  
26 4. Pneumonia. In: European Lung White Book. 2nd ed. Sheffield, UK: European  
27 Respiratory Society/European Lung Foundation, 2003:55-65. Available from:  
28 <http://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/> (accessed  
29  
30  
31  
32 2017 August 14)  
33  
34  
35  
36 5. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in  
37 the elderly: a population-based 12-year follow-up study. *Arch Intern Med*  
38  
39  
40 1999;159:1550-55.  
41  
42  
43 6. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired  
44 pneumonia in adults in Europe: a literature review. *Thorax* 2013;68:1057-65.  
45  
46  
47  
48 7. Quan TP, Fawcett NJ, Wrightson JM, et al. Increasing burden of community-  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 8. de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, et al. Trends in  
4 hospitalizations for community-acquired pneumonia in Spain: 2004 to 2013. *Eur J*  
5 *Intern Med* 2017;40:64-71.  
6  
7  
8  
9
- 10 9. Marrie TJ, Haldane EV, Faulkner RS, Durant H, Kwan C. Community-acquired  
11 pneumonia requiring hospitalization. Is it different in the elderly?. *J Am Geriatr Soc*  
12 1985;33:671-80.  
13  
14  
15
- 16 10. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day  
17 readmissions after hospitalization for heart failure, acute myocardial infarction, or  
18 pneumonia. *JAMA* 2013;309:355-63.  
19  
20  
21  
22
- 23 11. Kahlon S, Pederson J, Majumdar SR, et al. Association between frailty and 30-day  
24 outcomes after discharge from hospital. *CMAJ* 2015;187:799-804.  
25  
26  
27  
28
- 29 12. Tang VL, Halm EA, Fine MJ, et al. Predictors of rehospitalization after admission  
30 for pneumonia in the veterans affairs healthcare system. *J Hosp Med* 2014;9:379-83.  
31  
32  
33  
34
- 35 13. Steel K, Gertman P, Crescenzi C, Anderson J. Iatrogenic illness on a general  
36 medicine service at a university hospital. *N Engl J Med* 1981;304:638-42.  
37  
38
- 39 14. Elixhauser A, Steiner C. Readmissions to U.S. Hospitals by Diagnosis, 2010:  
40 Statistical Brief #153. 2013 Apr. In: Healthcare Cost and Utilization Project  
41 (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare  
42 Research and Quality (US); 2006 Feb-. Available from:  
43 <https://www.ncbi.nlm.nih.gov/books/NBK154385/> (accessed 2017 August 16)  
44  
45  
46  
47  
48
- 49 15. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on  
50 hospital discharge and the risk of adverse outcomes in patients with pneumonia.  
51 *Arch Intern Med* 2002;162:1278-84.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Dong T, Cursio JF, Qadir S, et al. Discharge disposition as an independent predictor  
4 of readmission among patients hospitalised for community-acquired pneumonia. *Int*  
5 *J Clin Pract* 2017;71:e12935.  
6  
7  
8  
9 17. Auerbach AD, Kripalani S, Vasilevskis EE, et al. Preventability and causes of  
10 readmissions in a national cohort of general medicine patients. *JAMA Intern Med*  
11 2016;176:484-93.  
12  
13  
14  
15  
16 18. Mykietiuk A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal  
17 vaccination on clinical outcome of hospitalized adults with community-acquired  
18 pneumococcal pneumonia. *Eur J Clin Microbiol Infect Dis* 2006;25:457-62.  
19  
20  
21  
22  
23 19. Neupane B, Walter SD, Krueger P, Marrie T, Loeb M. Predictors of inhospital  
24 mortality and re-hospitalization in older adults with community-acquired  
25 pneumonia: a prospective cohort study. *BMC Geriatr* 2010;10:22.  
26  
27  
28  
29  
30 20. Domínguez À, Soldevila N, Toledo D, et al. Effectiveness of 23-valent  
31 pneumococcal polysaccharide vaccination in preventing community-acquired  
32 pneumonia hospitalization and severe outcomes in the elderly in Spain. *PLoS One*  
33 2017;12:e0171943.  
34  
35  
36  
37  
38  
39  
40 21. Lindenauer PK, Normand S-LT, Drye EE, et al. Development, validation, and  
41 results of a measure of 30-day readmission following hospitalization for pneumonia.  
42 *J Hosp Med (Online)* 2011;6:142-50.  
43  
44  
45  
46  
47 22. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of  
48 readmission or mortality in pneumonia and heart failure: systematic review. *J Gen*  
49 *Intern Med* 2013;28:269-82.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23. Adamuz J, Viasus D, Campreciós-Rodríguez P, et al. A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. *Respirology* 2011;16:1119-26.
24. Capelastegui A, España Yandiola PP, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. *Chest* 2009;136:1079-85.
25. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. *Clin Infect Dis* 2008;46:550-56.
26. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med* 2009;360:1418-28.
27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. *Md State Med J* 1965;14:61-5.
28. Kats MH. Multivariable Analysis. A practical guide for clinicians and public health researchers. 3rd ed. New York, NY: Cambridge University Press; 2011:88-92.
29. Epstein AM, Jha AK, Orav EJ. The Relationship between Hospital Admission Rates and Rehospitalizations. *N Engl J Med* 2011;365:2287-95.
30. Bohannon R, Maljanian R. Hospital readmissions of elderly patients hospitalized with pneumonia. *Conn Med* 2003;67:599-603.
31. El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of Recurrent Hospitalization for Pneumonia in the Elderly. *J Am Geriatr Soc* 2004;52:2010-15.
32. O'Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure

1  
2 Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J* 2010;159:841-  
3 49.e1.  
4  
5

- 6  
7 33. Dunlay SM, Weston SA, Killian JM, Bell MR, Jaffe AS, Roger VL. Thirty-day  
8 rehospitalizations after acute myocardial infarction: a cohort study. *Ann Intern Med*  
9 2012;157:11-8.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1. Flowchart of hospital readmissions

40x26mm (300 x 300 DPI)



**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	7
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12
		(b) Report category boundaries when continuous variables were categorized	12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA IN OLDER PATIENTS. A CROSS-SECTIONAL STUDY IN SEVEN SPANISH REGIONS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020243.R1
Article Type:	Research
Date Submitted by the Author:	17-Jan-2018
Complete List of Authors:	Toledo, Diana; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Soldevila, Núria; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Torner, Nuria; Agència de Salut Pública de Catalunya, & Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Perez, M <sup>a</sup> José; Hospital Valme, UGC Prevención, Promoción y Vigilancia de la Salud Espejo, Elena; Hospital Universitari de Terrassa, Internal Medicine Navarro, Gemma; Hospital Parc Tauli, Egurrola, Mikel; Hospital de Galdakao Dominguez, Angela; Universitat de Barcelona, Medicina; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP)
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Infectious diseases, Public health, Geriatric medicine
Keywords:	Community acquired pneumonia, readmission, elderly, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3 FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER  
4 HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA IN OLDER  
5 PATIENTS. A CROSS-SECTIONAL STUDY IN SEVEN SPANISH REGIONS  
6  
7  
8

9 **Authors:** Diana Toledo,<sup>1,2</sup> Núria Soldevila,<sup>1,2</sup> Núria Torner,<sup>3,2,1</sup> M<sup>a</sup> José Pérez,<sup>4</sup> Elena  
10 Espejo,<sup>5</sup> Gemma Navarro,<sup>6</sup> Mikel Egurrola,<sup>7</sup> Ángela Domínguez,<sup>2,1</sup> and the Project FIS  
11  
12 PI12/02079 Working Group  
13  
14

15  
16 <sup>1</sup> Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud  
17 Pública, M.P (CIBERESP). Madrid, Spain  
18

19  
20 <sup>2</sup> Universitat de Barcelona, Barcelona, Spain  
21

22 <sup>3</sup> Agència de Salut Pública de Catalunya, Barcelona, Spain  
23

24 <sup>4</sup> Hospital Valme, Seville, Spain  
25

26 <sup>5</sup> Hospital de Terrassa, Terrassa, Spain  
27

28  
29 <sup>6</sup> Corporació Sanitària i Universitaria Parc Taulí, Barcelona, Spain  
30

31 <sup>7</sup> Hospital de Galdakao, Usansolo, Spain  
32  
33  
34

35 **Corresponding author:**  
36

37 Diana Toledo.  
38 Universitat de Barcelona,  
39 C/ Casanova, 143, 08036,  
40 Barcelona, Spain.  
41 Email: [diannitz@gmail.com](mailto:diannitz@gmail.com)  
42  
43

44 **Word count:** 2260  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** Hospital readmission in patients admitted for community-acquired pneumonia (CAP) is frequent in the elderly and patients with multiple comorbidities, resulting in a clinical and economic burden. The aim of this study was to determine factors associated with 30-day readmission in patients with CAP.

**Design:** A cross-sectional study.

**Setting:** The study was conducted in patients admitted to 20 hospitals in seven Spanish regions during two influenza seasons (2013-2014 and 2014-2015).

**Participants:** We included patients aged  $\geq 65$  years admitted through the emergency department with a diagnosis compatible with CAP. Patients who died during the initial hospitalization and those hospitalized  $>30$  days were excluded.

**Main outcome measures:** 30-day readmission.

**Results:** Factors associated with 30-day readmission were living with a person aged  $<15$  years (aOR 2.10, 95% CI 1.01-4.41),  $>3$  hospital visits during the 90 previous days (aOR 1.53; 95% CI 1.01-2.34), chronic respiratory failure (aOR 1.74, 95% CI 1.24-2.45), heart failure (aOR 1.69, 95% CI 1.21-2.35), chronic liver disease (aOR 2.27, 95% CI 1.20-4.31) and discharge to home with home health care (aOR 5.61, 95% CI 1.70-18.50). No associations were found with pneumococcal or seasonal influenza vaccination in any of the three previous seasons.

**Conclusions:** This study shows that 11.39% of patients aged  $\geq 65$  years initially hospitalized for CAP were readmitted within 30 days after discharge. Rehospitalization was associated with preventable and non-preventable factors.

**Strengths and limitations of this study**

- All the information on readmission was obtained from medical records.
- The study is part of a multi-center study carried out in seven autonomous communities representing 70% of the Spanish population.
- It was not possible to collect detailed information on the readmission episode.

For peer review only

## INTRODUCTION

Community-acquired pneumonia (CAP) is a frequent, potentially serious disease in people aged  $\geq 65$  years and one of the leading causes of hospitalization and mortality worldwide in this age group,[1-4] in whom recovery from an episode of CAP is predictive of increased mortality in subsequent years.[5]

The incidence of CAP differs between European countries due to variations in age distribution, the introduction of vaccination programs and the clinical guidelines used. However, the incidence of cases and hospitalizations increases with age in all countries.[6,7] In Spain, CAP is not a reportable disease and therefore the incidence in the population is unknown, although 2013 data also show an increase in hospitalization (394.04 per  $10^5$  in the 65-74 years age group and 2584.95 per  $10^5$  in the  $>85$  years age group).[8]

In people aged  $\geq 65$  years, full recovery after hospitalization due to CAP is usually slow and the probability of readmission during a period of time after discharge is greater.[9] 30-day readmission post discharge is usually used as an indicator of vulnerability.[2,10-12]

Readmission in patients admitted for CAP is relatively frequent (especially in the elderly and patients with multiple comorbidities), and is often associated with a worsening of a baseline disease or the appearance of a new pathology,[13] and this results in a significant clinical and economic burden for health systems.[2,14] Studies have explored the factors associated with readmission following hospitalization due to CAP, and have identified factors that improve the prognosis at discharge and are considered preventable, such as influenza and pneumococcal vaccination, the use of hospital care protocols, discharge planning and post-discharge follow-up. Adequate

1  
2 discharge planning, including patient stability and destination, has been associated with  
3 reduced readmission.[15-17] However, the effect of seasonal influenza and  
4 pneumococcal vaccination and the adequacy of hospital care (use of clinical guidelines  
5 and antibiotic plans) may be more controversial.[18-21] The initial severity of CAP,  
6 worsening of comorbidities and some individual patient characteristics have been  
7 described as non-preventable factors,[15,21-25] and factors such as age, sex,  
8 socioeconomic status, education and some comorbidities have been independently  
9 associated with a greater likelihood of readmission.[25,26]  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 The objective of this study was to determine the risk factors associated with 30-day  
22 readmission in people aged  $\geq 65$  years initially hospitalized due to CAP.  
23  
24  
25

## 26 MATERIALS AND METHODS

### 27 Study design

28 This cross-sectional study was carried out as part of a multicenter study in 20 hospitals  
29 from seven Spanish regions (Andalusia, the Basque Country, Castile and Leon,  
30 Catalonia, Madrid, Navarre, and Valencian Community). Patients aged  $\geq 65$  years  
31 hospitalized due to CAP in the participating hospitals during the 2013–2014 and 2014–  
32 2015 influenza seasons were recruited.  
33  
34  
35  
36  
37  
38  
39  
40

### 41 Study population

42 Patients included were aged  $\geq 65$  years admitted through the emergency department to  
43 any of the participating hospitals for  $\geq 24$  hours with a chest X-ray showing pulmonary  
44 infiltrate compatible with pneumonia and  $\geq 1$  of the following symptoms or signs of  
45 acute lower respiratory tract infection: cough, pleural chest pain, dyspnea, fever  $>38^{\circ}\text{C}$ ,  
46 hypothermia  $< 35^{\circ}\text{C}$ , and abnormal auscultator respiratory sounds unexplained by other  
47 causes.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57



1  
2  
3 Patients who died during the initial hospitalization and patients hospitalized for >30  
4 days were not included. Institutionalized patients, patients with nosocomial pneumonia  
5 (onset  $\geq$ 48 hours after hospital admission), patients whose main residence was not in  
6 any of the seven participating regions and those who did not provide signed informed  
7 consent were excluded.  
8  
9  
10  
11  
12

### 13 14 **Outcomes**

15  
16  
17 The dependent variable was 30-day readmission, defined as ‘hospitalization for any  
18 reason within 30 days of discharge’. Information on readmission was collected by re-  
19 view of index hospital medical records up to 30 days after initial discharge.  
20  
21  
22

23  
24 All participating hospitals had a specifically-trained team of health professionals who  
25 used a structured questionnaire to collect information by patient interview on  
26 confirmation of the case and review of medical records.  
27  
28  
29

30  
31 Information collected included sociodemographic variables: age, sex, marital status,  
32 educational level, cohabitation; lifestyle factors: smoking status (current smoker, ex-  
33 smoker, non-smoker) and high alcohol consumption (> 40 g/day in men, > 20 g/day in  
34 women); the Barthel index,[27] was used to assess the functional capacity at hospital  
35 admission (ranging from 0 - complete dependence - to 100 - complete independence).  
36  
37  
38

39  
40 Immunization history: patients were considered vaccinated against pneumococcal  
41 disease if they had receive a dose of pneumococcal vaccine in the last 5 years and  
42 against seasonal influenza if they had received a dose of the influenza vaccination at  
43 least 14 days before symptom onset. Risk medical conditions: comorbidities considered  
44 at high or moderate risk (chronic respiratory failure, history of pneumonia during the  
45 last two years, solid or hematologic neoplasm, diabetes mellitus, renal failure, chronic  
46 obstructive pulmonary disease (COPD), heart failure, disabling neurological disease,  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 chronic liver disease and hemoglobinopathy or anemia) were collected from medical  
4 records; comorbidities were assessed using the Charlson comorbidity index,[28] which  
5 assigns a weight to each comorbid condition (0 No comorbidity; 1 Low comorbidity and  
6 2 High comorbidity); Prior medical utilization (number of primary care nurse visits and  
7 number of hospital visits in the last 90 days) and hospital care process (severity of  
8 illness quantified in 5 risk classes using the Pneumonia Severity Index (PSI) at  
9 admission,[29] length of stay (LOS) <8 days and ≥8 days,[8] intensive care unit (ICU)  
10 admission, mechanical ventilation, adequacy of antibiotic treatment plan (validated  
11 according to clinical guidelines) (Yes/No) and discharge disposition (home without  
12 services, home with home health care or social health centre).[16]

### 24 25 **Statistical analysis**

26  
27  
28 The Barthel index, a continuous variable, was dichotomized into 0-89 (moderate-to-  
29 high degree of dependency) and ≥90 (little or no dependency).

30  
31  
32  
33 A bivariate analysis was conducted to compare 30-day readmission and no readmission  
34 according to sociodemographic variables, lifestyle factors, the Barthel index,  
35 immunization history, risk medical conditions, prior medical utilization and hospital  
36 care process. Independent variables were checked for collinearity using the variance  
37 inflation factor.[30]

38  
39  
40  
41  
42  
43  
44  
45 As Spanish regions have varying degrees of autonomy in organizing health services,  
46 persons living in the same region tend to have similar access to health care. Therefore,  
47 to estimate the crude odds ratio (cOR) and adjusted odds ratio (aOR), we used  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
multilevel regression models that considered the outcome variable in people from the  
same region to obtain accurate statistical estimates of predictors of 30-day

1  
2  
3 readmission.[30] Covariates were introduced into the model using a backward stepwise  
4  
5 procedure, with a cut-off point of  $p < 0.2$ .

6  
7 The analysis was performed using the SPSS v.24 statistical package and Rv3.3.0  
8  
9 statistical software.

### 10 11 12 13 **Ethical approval**

14  
15 The study was approved by the Ethics Committees of the participating hospitals.

### 16 17 18 19 **RESULTS**

20  
21 Overall, 1929 inpatients met all study eligibility criteria for CAP: 93 patients died  
22  
23 during the initial hospitalization and 80 were hospitalized for  $> 30$  days. Therefore, 1756  
24  
25 CAP cases were discharged within 30 days after the initial hospitalization: of these, 200  
26  
27 (11.39%) were readmitted within 30 days after hospital discharge (Figure 1).

28  
29  
30  
31 Figure 1. Flowchart of hospital readmissions

32  
33  
34 The reasons for 30-day readmission were unrelated to pneumonia in 49.5% (99 cases),  
35  
36 pneumonia-related in 44.5% (89 cases) and unknown diagnosis in 6% (12 cases).

37  
38  
39 The descriptive analysis and unadjusted associations of factors related to 30-day  
40  
41 readmission are shown in table 1. No differences were observed according to lifestyle  
42  
43 factors and immunization history.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Distribution of 30-day readmission cases according to patient characteristics

	Readmission n=200	No Readmission n=1556	Crude OR	p value
<b>Sociodemographic</b>				
<b>Age median (range)</b>	80 (65-101)	78 (64-100)	1.02 (0.99-1.04)	0.07
<b>Age group</b>				
65-74 y.	56 (28.0%)	501 (32.2%)	1	
75-84 y.	98 (49.0%)	729 (46.9%)	1.20 (0.85-1.70)	0.31
>84 y.	46 (23.0%)	326 (20.5%)	1.26 (0.83-1.91)	0.27
<b>Sex</b>				
Female	64 (32.0%)	622 (40.0%)	1	
Male	136 (68.0%)	934 (60.0%)	1.44 (1.05 – 1.97)	0.02
<b>Educational level</b>				
No/primary education	153 (78.1%)	1118 (72.4%)	1	
Secondary or higher	43 (21.9%)	427 (27.6%)	0.75 (0.51-1.10)	0.14
<b>Marital status</b>				
Married/Cohabiting	116 (58.0%)	912 (58.6%)	1	
Single	21 (10.5%)	107 (6.9%)	1.56 (0.94-2.59)	0.09
Widowed/divorced	63 (31.5%)	536 (34.4%)	0.93 (0.67-1.29)	0.66
<b>Cohabitation</b>				
Lives alone	31 (15.5%)	289 (18.6%)	1	
Lives with cohabitant aged >15 y.	155 (77.5%)	1203 (77.4%)	1.20 (0.80 – 1.80)	0.39
Lives with cohabitant aged <15 y.	14 (7.0%)	63 (4.1%)	2.03 (1.02 – 4.04)	0.04
<b>Lifestyle factors</b>				
<b>Smoking status</b>				
Non smoker	79 (39.5%)	693 (44.5%)	1	
Smoker	16 (8.0%)	138 (8.9%)	1.04 (0.59-1.83)	0.90
Ex-smoker	105 (52.5%)	725 (46.6%)	1.28 (0.94-1.75)	0.11
<b>High alcohol consumption</b>				
No	197 (98.5%)	1524 (97.9%)	1	
Yes	3 (1.5%)	32 (2.1%)	1.38 (0.42-4.54)	0.60
<b>Prior utilization of resources</b>				
<b>N° of nurse visits in last 90d</b>				
0-2	147 (73.5%)	1182 (76.4%)	1	
≥3	53 (26.5%)	365 (23.6%)	1.17 (0.82-1.65)	0.39
<b>N° of hospital visits in last 90d</b>				
0-2	164 (82.8%)	1355 (87.6%)	1	
≥3	34 (17.2%)	192 (12.4%)	1.53 (1.02-2.31)	0.04
<b>Barthel index</b>				
Little or no dependency >90	108 (54.0%)	990 (63.6%)	1	
Moderate-to-high dependency ≤90	92 (46.0%)	566 (36.4%)	1.47 (1.08-2.01)	0.01
<b>Immunizations</b>				
<b>Influenza vaccination in any of the 3 previous seasons</b>				
No	54 (27.0%)	464 (29.8%)	1	
Yes	146 (73.0%)	1092 (70.2%)	1.16 (0.83-1.61)	0.39
<b>Pneumococcal vaccination in 5 previous years</b>				
No	161 (80.5%)	1281 (82.3%)	1	
Yes	39 (19.5%)	275 (17.7%)	1.11 (0.76-1.62)	0.58
<b>Risk medical conditions</b>				
<b>Chronic respiratory failure</b>				
No	136 (68.0%)	1269 (81.6%)	1	
Yes	64 (32.0%)	287 (18.4%)	2.08 (1.50 – 2.88)	<0.001

<b>Pneumonia during the last 2 years</b>				
No	146 (73.0%)	1267 (81.4%)	1	
Yes	54 (27.0%)	289 (18.6%)	1.65 (1.18 – 2.32)	0.004
<b>Any malignancy</b>				
No	161 (80.5%)	1271 (81.7%)	1	
Yes	39 (19.5%)	285 (18.3%)	1.08 (0.74 – 1.58)	0.67
<b>Diabetes</b>				
No	139 (69.5%)	1023 (65.7%)	1	
Yes	61 (30.5%)	533 (34.3%)	0.83 (0.60 – 1.14)	0.26
<b>Renal failure</b>				
No	151 (75.5%)	1263 (81.2%)	1	
Yes	49 (24.5%)	293 (18.8%)	1.38 (0.97 – 1.96)	0.07
<b>COPD</b>				
No	128 (64.0%)	1074 (69.0%)	1	
Yes	72 (36.0%)	482 (31.0%)	1.25 (0.92 – 1.70)	0.16
<b>Heart failure</b>				
No	128 (64.0%)	1168 (75.1%)	1	
Yes	72 (36.0%)	388 (24.9%)	1.69 (1.24 – 2.31)	0.001
<b>Chronic liver disease</b>				
No	186 (93.0%)	1504 (96.7%)	1	
Yes	14 (7.0%)	52 (3.3%)	2.13 (1.15 – 3.94)	0.01
<b>Hemoglobinopathy or anemia</b>				
No	160 (80.0%)	1324 (85.1%)	1	
Yes	40 (20.0%)	232 (14.9%)	1.40 (0.96 – 2.04)	0.08
<b>Disabling neurological disease</b>				
No	179 (89.5%)	1416 (91.0%)	1	
Yes	21 (10.5%)	140 (9.0%)	1.17 (0.72 – 1.90)	0.52
<b>Charlson Index</b>				
No comorbidity (0)	18 (9.0%)	233 (15.0%)	1	
Low comorbidity (1)	54 (27.0%)	378 (24.3%)	1.83 (1.05-3.20)	0.03
High comorbidity ( $\geq 2$ )	128 (64.0%)	945 (60.7%)	1.71 (1.02-2.86)	0.04
<b>Hospital care process</b>				
<b>ICU</b>				
No	188 (94.5%)	1499 (96.9%)	1	
Yes	11 (5.5%)	48 (3.1%)	1.93 (0.97 – 3.81)	0.06
<b>Mechanical ventilation</b>				
No	157 (78.5%)	1317 (84.9%)	1	
Yes	43 (21.5%)	235 (15.1%)	1.50 (1.03 – 2.18)	0.03
<b>Pneumonia severity index (PSI)</b>				
I-III	69 (34.7%)	645 (41.7%)	1	
IV-V	130 (65.3%)	902 (58.3%)	1.40 (1.02 – 1.92)	0.04
<b>Length of hospital stay (LOS)</b>				
<8 days	80 (40.0%)	766 (49.2%)	1	
$\geq 8$ days	120 (60.0%)	790 (50.8%)	1.45 (1.05 – 2.02)	0.02
<b>Antibiotic treatment</b>				
No	97 (50.3%)	700 (46.6%)	1	
Yes	96 (49.7%)	802 (53.4%)	1.07 (0.76 – 1.50)	0.70
<b>Discharge disposition</b>				
Home without services	185 (92.5%)	1477 (94.9%)	1	
Home with home health care	9 (4.5%)	19 (1.2%)	5.05 (1.58 – 16.15)	0.01
Social health centre	6 (3.0%)	60 (3.9%)	1.23 (0.41 – 2.92)	0.63

COPD: Chronic obstructive pulmonary disease.

Table 2. Multilevel regression analysis of factors associated with 30-day readmission.

	aOR	p value
<b>Age</b>	1.02 (0.99-1.04)	0.13
<b>Sex-Male</b>	1.39 (0.99-3.12)	0.06
<b>Cohabitation</b>		
Lives alone	1	
Lives with cohabitant aged >15 y.	1.17 (0.71-1.95)	0.54
Lives with cohabitant aged <15 y.	2.10 (1.01-4.41)	0.04
<b>Marital status</b>		
Married/Cohabiting	1	
Single	1.73 (0.96-3.11)	0.07
Widowed/Divorced	0.94 (0.61-1.44)	0.77
<b>Nº. of hospital visits ≥3</b>	1.53 (1.01-2.34)	0.04
<b>Barthel index</b>		
Moderate-to-high dependency ≤90	1.39 (0.99-1.95)	0.05
<b>Pneumonia during the last 2 years</b>	1.31 (0.91-1.88)	0.14
<b>Chronic respiratory failure</b>	1.74 (1.24-2.45)	0.001
<b>Diabetes</b>	0.74 (0.53-1.04)	0.08
<b>Heart failure</b>	1.69 (1.21-2.35)	0.002
<b>Chronic liver disease</b>	2.27 (1.20-4.31)	0.01
<b>Mechanical ventilation</b>	1.33 (0.90-1.97)	0.15
<b>Discharge disposition</b>		
Home without services	1	
Home with home health care	5.61 (1.70-18.50)	0.005
Social health centre	1.27 (0.53-3.05)	0.59

Factors independently associated with 30-day readmission in the multilevel analysis (Table 2) were living with a person aged < 15 years (aOR 2.10, 95% CI 1.01-4.41; p=0.04), > 3 hospital visits during the 90 previous days (aOR 1.53; 95% CI 1.01-2.34; p=0.04) chronic respiratory failure (aOR 1.74, 95% CI 1.24-2.45; p=0.001), heart failure (aOR 1.69, 95% CI 1.21-2.35; p=0.002), chronic liver disease (aOR 2.27, 95% CI 1.21-4.36; p=0.01) and discharge to home with home health care (aOR 5.61, 95% CI 1.70-18.50; p=0.005).

A moderate-to-high degree of dependency was tentatively associated with readmission (aOR 1.39, 95% CI 0.99-1.95; p=0.05).

1  
2  
3 No associations were observed with age, sex, pneumococcal vaccination or seasonal  
4 influenza vaccination in any of the three previous seasons, the PSI, or any variable  
5 related to the hospital care process.  
6  
7  
8  
9

## 10 **DISCUSSION**

11  
12 The overall 30-day readmission rate in our study was 11.39%. Although all  
13 participating hospitals were referral centers, readmission rates ranged between regions  
14 from 2.5% to 14%. This might be due to the differences in the hospital healthcare  
15 burden of participating hospitals and in the protocols used.  
16  
17  
18  
19  
20  
21

22 In the Pneumonia Patient Outcomes Research Team (PORT) cohort study, carried out in  
23 the United States and Canada, the readmission rate in adults was 10.1%.[31]

24  
25 Readmission rates at 30 days in people aged  $\geq 65$  years admitted for CAP vary between  
26 8% and 27%, depending on the population and country studied.[11,19,21,25,32] In  
27  
28  
29 Spain, national data show 30-days readmissions increased from 11.5% in 2004 to 13.5%  
30 in 2013 in adults admitted for CAP.[8]  
31  
32  
33  
34  
35

36 Our results show that non-preventable factors, specifically patient characteristics (living  
37 with a person aged  $< 15$  years,  $> 3$  hospital visits during the 90 previous days and some  
38 comorbidities) and one preventable factor (discharge disposition) were significantly  
39 associated with 30-day readmission. Factors such as cohabitation and the discharge  
40 disposition have been little studied and their identification provides a new perspective on  
41 the risk factors involved in 30-day readmission of these patients.  
42  
43  
44  
45  
46  
47  
48  
49

50 Calvillo-King et al. in a thorough review of studies on readmission, underlined the  
51 importance of considering social factors (sociodemographic, socioeconomic and the  
52 social environment) as elements that could influence readmission after an episode of  
53 CAP. [22] Our study evaluated sociodemographic and socioeconomic factors and the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 social environment. Although the influence of sex varies between studies and may be  
4  
5 closely related to other factors such as age, risk habits and some comorbidities, the  
6  
7 association with male sex disappeared in the final model, in contrast to the results found  
8  
9 by Neupane et al. and Bohannon et al.[19,33]  
10

11  
12 Patients living with children aged <15 years had a two-fold higher probability of  
13  
14 readmission than those living alone or with a partner. Although it is known that  
15  
16 schoolchildren may be a source of infection of the elderly in some infectious diseases,  
17  
18 we found no studies that investigated the type of cohabitation in this context, possibly  
19  
20 because one factor usually associated with readmission in people aged  $\geq 65$  years is  
21  
22 living in geriatric residences.[11] In Spain, the recommendation of vaccination of  
23  
24 persons in contact with high-risk persons, including persons aged  $\geq 65$  years with risk  
25  
26 factors has been maintained.[34] We also found no association with factors identified by  
27  
28 other authors, such as the educational level or the history of smoking or alcohol  
29  
30 use.[25,35]  
31  
32  
33

34  
35 In the studies by Neupane et al. in two Canadian cities and Adamuz et al. in a tertiary  
36  
37 hospital in Barcelona, seasonal influenza and pneumococcal vaccination were included  
38  
39 in the adjusted analysis of readmission due to CAP, but no association was  
40  
41 found.[19,23] We investigated seasonal influenza and pneumococcal vaccination in the  
42  
43 previous five years but found no association in the crude or adjusted models.  
44  
45

46  
47 In our study, 49.5% of 30-day readmissions were due to causes unrelated to CAP and  
48  
49 91% of readmitted patients presented comorbidities. Patients with chronic liver disease,  
50  
51 heart failure and respiratory failure had higher 30-day readmission rates, findings  
52  
53 consistent with other studies showing that some cardiovascular and respiratory diseases  
54  
55 play an important role in the risk of readmission in patients with CAP,[12,23-25,36] and  
56  
57  
58  
59  
60



1  
2  
3 that the reason for readmission generally differs from the initial diagnosis of CAP due,  
4  
5 in most cases, to destabilization of comorbidities.[10.23-26,37,38] Fine et al., in a  
6  
7 cohort study, found that pneumonia often occurs in patients with underlying  
8  
9 comorbidities and often results in a worsening of such underlying conditions.[31]  
10

11  
12 We found an association with prior hospital utilization in the 90 days before admission  
13  
14 for CAP, but no association with GP and primary care nurse visits. Health care in Spain  
15  
16 is free, which encourages patients to make multiple visits to primary care centers and/or  
17  
18 hospitals, ensuring patient care and follow-up. Adamuz et al. and Tang et al. found an  
19  
20 association between readmission and hospitalization in the 90 days before admission for  
21  
22 CAP.[11.23]  
23

24  
25  
26 One preventable factor that influences CAP episodes in people aged  $\geq 65$  years is the  
27  
28 quality of care received during hospitalization, while discharge planning and follow-up  
29  
30 until recovery influence patient recovery and, therefore, readmission.[16,21,23,24] We  
31  
32 found, as did Dong et al.,[16] an association with discharge to home with home health  
33  
34 care. A possible explanation might be an inadequate evaluation of the patient's stability  
35  
36 at discharge. Various authors have suggested the importance of the discharge disposition  
37  
38 in patients admitted due to other causes. However, with respect to patients with CAP,  
39  
40 only Dong et al. and the present study have found an association between the discharge  
41  
42 disposition and readmission. Other variables related to the quality of care were studied to  
43  
44 assess these aspects but no association with readmission was found.  
45  
46  
47

### 48 **Strengths and limitations**

49

50 The main strength of the study is that all clinical information was obtained from patient  
51  
52 medical records and, therefore, was unlikely to be biased. Another strength is the cross-  
53  
54  
55  
56  
57

1  
2  
3 sectional design, as it is part of a multi-center study carried out in seven regions  
4  
5 representing 70% of the Spanish population.  
6

7  
8 A limitation is that it was not possible to collect patient characteristics at discharge, and  
9  
10 therefore we cannot say whether there was instability at discharge that may have caused  
11  
12 the readmission. Therefore the variable 'discharge disposition' was considered as a  
13  
14 proxy to define instability.  
15

## 16 17 **CONCLUSIONS**

18  
19 In conclusion, this study shows that 11.39% of patients aged  $\geq 65$  years hospitalized due  
20  
21 to CAP are readmitted within 30 days after an episode of CAP and that this was  
22  
23 associated with living with a cohabitant aged  $<15$  years,  $>3$  hospital visits during the 90  
24  
25 previous days, chronic respiratory failure, heart failure, chronic liver disease and  
26  
27 discharge to home with home health care services.  
28

29  
30  
31 Because social factors, in addition to post-discharge and pre-readmission clinical  
32  
33 information, may influence the prognosis, it is important that these factors continue to  
34  
35 be considered in future research.  
36

37  
38 **Author contributions:** DT, is the guarantor of this article. DT, MJP, EE, GN, ME and  
39  
40 AD, designed the research. DT, and NS conducted the statistical analyses. DT, NT and  
41  
42 AD wrote the initial draft of the manuscript, and DT, NS, NT, MJP, EE, GN, ME and  
43  
44 AD reviewed the manuscript for accuracy and scientific content.  
45

46  
47 **A funding statement:** This study was supported by the Institute of Health Carlos III  
48  
49 with the European Regional Development Fund (FEDER) (PI12/02079) and the Catalan  
50  
51 Agency for the Management of Grants for University Research (AGAUR Grant number  
52  
53 2014/ SGR 1403). The funders had no role in the study design, data collection and  
54  
55 analysis, decision to publish, or preparation of the manuscript.  
56  
57

1  
2  
3 **Competing interests:** The authors declare no competing interests.  
4

5  
6 **Data Sharing Statement:** No additional data available.  
7

8  
9 **Acknowledgements:** The members of the Project PI12/02079 Working Group are, by  
10 region: Andalusia: JM Mayoral (in memoriam) (Servicio de Vigilancia de Andalucía), J  
11 Díaz-Borrego (Servicio Andaluz de Salud), A Morillo (Hospital Universitario Virgen  
12 del Rocío), MJ Pérez-Lozano (Hospital Universitario Virgen de Valme), J Gutiérrez  
13 (Hospital Universitario Puerta del Mar), M Pérez-Ruiz, MA Fernández-Sierra  
14 (Complejo Hospitalario Universitario de Granada). Castile and Leon: S Tamames  
15 (Dirección General de Salud Pública, Investigación, Desarrollo e Innovación, Junta de  
16 Castilla y León), S Rojo-Rello (Hospital Clínico Universitario de Valladolid), R Ortiz  
17 de Lejarazu (Universidad de Valladolid), MI Fernández-Natal (Complejo Asistencial  
18 Universitario de León), T Fernández-Villa (GIIGAS-Grupo de Investigación en  
19 Interacción Gen-Ambiente y Salud, Universidad de León), A Pueyo (Hospital  
20 Universitario de Burgos), V Martín (Universidad de León; CIBERESP). Catalonia: A  
21 Vilella (Hospital Clínic), M Campins, A Antón (Hospital Universitari Vall d'Hebron;  
22 Universitat Autònoma de Barcelona), G Navarro (Corporació Sanitària i Universitaria  
23 Parc Taulí), M Riera (Hospital Universitari Mútua Terrassa), E Espejo (Hospital de  
24 Terrassa), MD Mas, R Pérez (ALTHAIA, Xarxa Hospitalaria de Manresa), JA Cayla, C  
25 Rius (Agència de Salut Pública de Barcelona; CIBERESP), P Godoy (Agència de Salut  
26 Pública de Catalunya; Institut de Recerca Biomèdica de Lleida, Universitat de Lleida;  
27 CIBERESP), N Torner (Agència de Salut Pública de Catalunya; Universitat de  
28 Barcelona; CIBERESP), C Izquierdo, R Torra (Agència de Salut Pública de Catalunya),  
29 L Force (Hospital de Mataró), A Domínguez, N Soldevila, I Crespo (Universitat de  
30 Barcelona; CIBERESP), D Toledo (Universitat de Barcelona). Valencia Community:  
31 M. Morales-Suárez-Varela (Universidad de Valencia; CIBERESP), F. Sanz (Consorti  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Hospital General Universitari de Valencia). Madrid: J Astray, MF Domínguez-Berjon,  
4 MA Gutiérrez, S Jiménez, E Gil, F Martín, R Génova-Maleras (Consejería de Sanidad),  
5 MC Prados, F. Enzzine de Blas, MA Salvador, S Rodríguez, M Romero (Hospital  
6  
7 Universitario la Paz), JC Galán, E Navas, L Rodríguez (Hospital Ramón y Cajal), CJ  
8  
9 Álvarez, E Banderas, S Fernandez (Hospital Universitario 12 de Octubre). Basque  
10  
11 Country: M Egurrola, MJ López de Goicoechea (Hospital de Galdakao). Navarre: J  
12  
13 Chamorro (Complejo Hospitalario de Navarra), I Casado, J Díaz-González, J Castilla  
14  
15 (Instituto de Salud Pública de Navarra; Instituto de Investigación Sanitaria de Navarra;  
16  
17 CIBERESP).  
18  
19  
20  
21  
22  
23  
24

## 25 **References**

- 26  
27  
28 1. Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients.  
29  
30 *Clin Geriatr Med* 2007;23:515-34.  
31  
32
- 33 2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-  
34  
35 acquired pneumonia among adults in Europe. *Thorax* 2012;67:71-9.  
36  
37
- 38 3. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal  
39  
40 disease in adults. *Clin Microbiol Infect* 2012;18(Suppl5):7-14.  
41  
42
- 43 4. Pneumonia. In: European Lung White Book. 2nd ed. Sheffield, UK: European  
44  
45 Respiratory Society/European Lung Foundation, 2003:55-65. Available from:  
46  
47 <http://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/> (accessed  
48  
49 2017 August 14)  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 5. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in  
4  
5 the elderly: a population-based 12-year follow-up study. *Arch Intern Med*  
6  
7 1999;159:1550-55.  
8  
9
- 10 6. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired  
11  
12 pneumonia in adults in Europe: a literature review. *Thorax* 2013;68:1057-65.  
13  
14
- 15 7. Quan TP, Fawcett NJ, Wrightson JM, et al. Increasing burden of community-  
16  
17 acquired pneumonia leading to hospitalisation, 1998-2014. *Thorax* 2016;71:535-42.  
18  
19
- 20 8. de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, et al. Trends in  
21  
22 hospitalizations for community-acquired pneumonia in Spain: 2004 to 2013. *Eur J*  
23  
24 *Intern Med* 2017;40:64-71.  
25  
26
- 27 9. Marrie TJ, Haldane EV, Faulkner RS, Durant H, Kwan C. Community-acquired  
28  
29 pneumonia requiring hospitalization. Is it different in the elderly?. *J Am Geriatr Soc*  
30  
31 1985;33:671-80.  
32  
33
- 34 10. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day  
35  
36 readmissions after hospitalization for heart failure, acute myocardial infarction, or  
37  
38 pneumonia. *JAMA* 2013;309:355-63.  
39  
40
- 41 11. Kahlon S, Pederson J, Majumdar SR, et al. Association between frailty and 30-day  
42  
43 outcomes after discharge from hospital. *CMAJ* 2015;187:799-804.  
44  
45  
46
- 47 12. Tang VL, Halm EA, Fine MJ, et al. Predictors of rehospitalization after admission  
48  
49 for pneumonia in the veterans affairs healthcare system. *J Hosp Med* 2014;9:379-83.  
50  
51
- 52 13. Steel K, Gertman P, Crescenzi C, Anderson J. Iatrogenic illness on a general  
53  
54 medicine service at a university hospital. *N Engl J Med* 1981;304:638-42.  
55  
56  
57

- 1  
2  
3 14. Elixhauser A, Steiner C. Readmissions to U.S. hospitals by diagnosis, 2010:  
4  
5 statistical brief #153. 2013 Apr. In: Healthcare Cost and Utilization Project (HCUP)  
6  
7 Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and  
8  
9 Quality (US); 2006 Feb-. Available from:  
10  
11 <https://www.ncbi.nlm.nih.gov/books/NBK154385/> (accessed 2017 August 16)  
12
- 13  
14 15. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on  
15  
16 hospital discharge and the risk of adverse outcomes in patients with pneumonia.  
17  
18 *Arch Intern Med* 2002;162:1278-84.  
19
- 20  
21 22 16. Dong T, Cursio JF, Qadir S, et al. Discharge disposition as an independent predictor  
22  
23 of readmission among patients hospitalised for community-acquired pneumonia. *Int*  
24  
25 *J Clin Pract* 2017;71:e12935.  
26
- 27  
28 29 17. Auerbach AD, Kripalani S, Vasilevskis EE, et al. Preventability and causes of  
30  
31 readmissions in a national cohort of general medicine patients. *JAMA Intern Med*  
32  
33 2016;176:484-93.  
34
- 35  
36 37 18. Mykietiuik A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal  
38  
39 vaccination on clinical outcome of hospitalized adults with community-acquired  
40  
41 pneumococcal pneumonia. *Eur J Clin Microbiol Infect Dis* 2006;25:457-62.  
42
- 43  
44 45 19. Neupane B, Walter SD, Krueger P, Marrie T, Loeb M. Predictors of inhospital  
46  
47 mortality and re-hospitalization in older adults with community-acquired  
48  
49 pneumonia: a prospective cohort study. *BMC Geriatr* 2010;10:22.  
50
- 51  
52 53 20. Domínguez À, Soldevila N, Toledo D, et al. Effectiveness of 23-valent  
54  
55 pneumococcal polysaccharide vaccination in preventing community-acquired  
56  
57 pneumonia hospitalization and severe outcomes in the elderly in Spain. *PLoS One*  
58  
59 2017;12:e0171943.  
60

- 1  
2  
3 21. Lindenauer PK, Normand S-LT, Drye EE, et al. Development, validation, and  
4 results of a measure of 30-day readmission following hospitalization for pneumonia.  
5  
6 *J Hosp Med (Online)* 2011;6:142-50.  
7  
8  
9  
10 22. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of  
11 readmission or mortality in pneumonia and heart failure: systematic review. *J Gen*  
12  
13 *Intern Med* 2013;28:269-82.  
14  
15  
16  
17 23. Adamuz J, Viasus D, Campreciós-Rodríguez P, et al. A prospective cohort study of  
18 healthcare visits and rehospitalizations after discharge of patients with community-  
19  
20 acquired pneumonia. *Respirology* 2011;16:1119-26.  
21  
22  
23  
24 24. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term  
25 rehospitalization following discharge of patients hospitalized with community-  
26  
27 acquired pneumonia. *Chest* 2009;136:1079-85.  
28  
29  
30  
31 25. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors  
32 for rehospitalization of patients hospitalized with community-acquired pneumonia.  
33  
34 *Clin Infect Dis* 2008;46:550-56.  
35  
36  
37  
38 26. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the  
39 Medicare fee-for-service program. *N Engl J Med* 2009;360:1418-28.  
40  
41  
42  
43 27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. *Md State Med J*  
44 1965;14:61-5.  
45  
46  
47  
48 28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic  
49 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*  
50 1987;40:373-83.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 29. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients  
4 with community-acquired pneumonia. *N Engl J Med* 1997;336:243-50  
5  
6  
7 30. Kats MH. *Multivariable Analysis. A practical guide for clinicians and public health*  
8 *researches*. 3rd ed. New York, NY: Cambridge University Press; 2011:88-92.  
9  
10  
11 31. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients  
12 with community-acquired pneumonia: results from the Pneumonia Patient  
13 Outcomes Research Team (PORT) cohort study. *Arch Intern Med* 1999;159:970-80.  
14  
15  
16 32. Epstein AM, Jha AK, Orav EJ. The relationship between hospital admission rates  
17 and rehospitalizations. *N Engl J Med* 2011;365:2287-95.  
18  
19  
20 33. Bohannon R, Maljanian R. Hospital readmissions of elderly patients hospitalized  
21 with pneumonia. *Conn Med* 2003;67:599–603.  
22  
23  
24  
25  
26  
27 34. Ministerio de Sanidad, Servicios Sociales e Igualdad. La Gripe.  
28  
29 <https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm>  
30  
31 (accessed 2017 December 22)  
32  
33  
34 35. El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of recurrent  
35 hospitalization for pneumonia in the elderly. *J Am Geriatr Soc* 2004;52:2010-15.  
36  
37  
38 36. Millett ER, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in  
39 the 28 days following a community-acquired pneumonia diagnosis in older adults,  
40 and their contribution to increasing hospitalisation rates over time: a cohort study.  
41  
42 *BMJ Open* 2015;5:e008737.  
43  
44  
45  
46 37. O'Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization in  
47 patients hospitalized with worsening heart failure and reduced left ventricular  
48 ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure  
49 Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J* 2010;159:841-  
50  
51 49.e1.  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 38. Dunlay SM, Weston SA, Killian JM, Bell MR, Jaffe AS, Roger VL. Thirty-day  
4  
5 rehospitalizations after acute myocardial infarction: a cohort study. *Ann Intern Med*  
6  
7 2012;157:11-8.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flowchart of hospital readmissions

88x59mm (300 x 300 DPI)

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/ line 3-5
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5/line 21-23
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5/line 30
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5/line 30-38
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5/line 44-55 6/line 2-12
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6/line 17-56 7/line 3-23
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6/line 17-56 7/line 3-23
Bias	9	Describe any efforts to address potential sources of bias	6/line 17-56 7/line 3-23
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7/line 28-30
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7/line 33-54 8/line 3-9
		(b) Describe any methods used to examine subgroups and interactions	7/line 33-54 8/line 3-9
		(c) Explain how missing data were addressed	7/line 14-23

			8/line 1-2
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	7/line 14-23 8/line 1-2
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8/ line 22-29
		(b) Give reasons for non-participation at each stage	8/ line 22-29
		(c) Consider use of a flow diagram	8 / line 32
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8/35-45 Page 9-10
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11/line36-55
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	12/ line 13-47
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14/line 51-53 15/ line 3-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12/ line 12-55 13/ line 3-55 14/ line 6-46
Generalisability	21	Discuss the generalisability (external validity) of the study results	15/ line 20-36
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15/ line 48-57

1  
2  
3  
4 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.  
5

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
7 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
8 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

# BMJ Open

## FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA IN OLDER PATIENTS. A CROSS-SECTIONAL STUDY IN SEVEN SPANISH REGIONS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020243.R2
Article Type:	Research
Date Submitted by the Author:	16-Feb-2018
Complete List of Authors:	Toledo, Diana; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Soldevila, Núria; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Torner, Nuria; Agència de Salut Pública de Catalunya, & Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP); Universitat de Barcelona, Medicina Perez, M <sup>a</sup> José; Hospital Valme, UGC Prevención, Promoción y Vigilancia de la Salud Espejo, Elena; Hospital Universitari de Terrassa, Internal Medicine Navarro, Gemma; Hospital Parc Tauli, Egurrola, Mikel; Hospital de Galdakao Dominguez, Angela; Universitat de Barcelona, Medicina; Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, M.P (CIBERESP) Working Group, Project FIS PI12/02079 ; Instituto de Salud Carlos III
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Infectious diseases, Public health, Geriatric medicine
Keywords:	Community acquired pneumonia, readmission, elderly, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3 FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER  
4 HOSPITALIZATION FOR COMMUNITY-ACQUIRED PNEUMONIA IN OLDER  
5 PATIENTS. A CROSS-SECTIONAL STUDY IN SEVEN SPANISH REGIONS  
6  
7  
8

9 **Authors:** Diana Toledo,<sup>1,2</sup> Núria Soldevila,<sup>1,2</sup> Núria Torner,<sup>3,2,1</sup> M<sup>a</sup> José Pérez,<sup>4</sup> Elena  
10 Espejo,<sup>5</sup> Gemma Navarro,<sup>6</sup> Mikel Egurrola,<sup>7</sup> Ángela Domínguez,<sup>2,1</sup> and the Project FIS  
11  
12 PI12/02079 Working Group  
13  
14

15  
16 <sup>1</sup> Consorcio Centro de Investigación Biomédica en Red de Epidemiología y Salud  
17 Pública, M.P (CIBERESP). Madrid, Spain  
18

19  
20 <sup>2</sup> Universitat de Barcelona, Barcelona, Spain  
21

22 <sup>3</sup> Agència de Salut Pública de Catalunya, Barcelona, Spain  
23

24 <sup>4</sup> Hospital Valme, Seville, Spain  
25

26 <sup>5</sup> Hospital de Terrassa, Terrassa, Spain  
27

28  
29 <sup>6</sup> Corporació Sanitària i Universitaria Parc Taulí, Barcelona, Spain  
30

31 <sup>7</sup> Hospital de Galdakao, Usansolo, Spain  
32  
33  
34

35 **Corresponding author:**  
36

37 Diana Toledo.  
38 Universitat de Barcelona,  
39 C/ Casanova, 143, 08036,  
40 Barcelona, Spain.  
41 Email: [diannitz@gmail.com](mailto:diannitz@gmail.com)  
42  
43

44 **Word count:** 2260  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** Hospital readmission in patients admitted for community-acquired pneumonia (CAP) is frequent in the elderly and patients with multiple comorbidities, resulting in a clinical and economic burden. The aim of this study was to determine factors associated with 30-day readmission in patients with CAP.

**Design:** A cross-sectional study.

**Setting:** The study was conducted in patients admitted to 20 hospitals in seven Spanish regions during two influenza seasons (2013-2014 and 2014-2015).

**Participants:** We included patients aged  $\geq 65$  years admitted through the emergency department with a diagnosis compatible with CAP. Patients who died during the initial hospitalization and those hospitalized  $>30$  days were excluded. Finally, 1756 CAP cases were included and of these, 200 (11.39%) were readmitted.

**Main outcome measures:** 30-day readmission.

**Results:** Factors associated with 30-day readmission were living with a person aged  $<15$  years (aOR 2.10, 95% CI 1.01-4.41),  $>3$  hospital visits during the 90 previous days (aOR 1.53; 95% CI 1.01-2.34), chronic respiratory failure (aOR 1.74, 95% CI 1.24-2.45), heart failure (aOR 1.69, 95% CI 1.21-2.35), chronic liver disease (aOR 2.27, 95% CI 1.20-4.31) and discharge to home with home health care (aOR 5.61, 95% CI 1.70-18.50). No associations were found with pneumococcal or seasonal influenza vaccination in any of the three previous seasons.

**Conclusions:** This study shows that 11.39% of patients aged  $\geq 65$  years initially hospitalized for CAP were readmitted within 30 days after discharge. Rehospitalization was associated with preventable and non-preventable factors.



**Strengths and limitations of this study**

- All the information on readmission was obtained from medical records.
- The study is part of a multi-center study carried out in seven autonomous communities representing 70% of the Spanish population.
- It was not possible to collect detailed information on the readmission episode.

For peer review only

## INTRODUCTION

Community-acquired pneumonia (CAP) is a frequent, potentially serious disease in people aged  $\geq 65$  years and one of the leading causes of hospitalization and mortality worldwide in this age group,[1-4] in whom recovery from an episode of CAP is predictive of increased mortality in subsequent years.[5]

The incidence of CAP differs between European countries due to variations in age distribution, the introduction of vaccination programs and the clinical guidelines used. However, the incidence of cases and hospitalizations increases with age in all countries.[6,7] In Spain, CAP is not a reportable disease and therefore the incidence in the population is unknown, although 2013 data also show an increase in hospitalization (394.04 per  $10^5$  in the 65-74 years age group and 2584.95 per  $10^5$  in the  $>85$  years age group).[8]

In people aged  $\geq 65$  years, full recovery after hospitalization due to CAP is usually slow and the probability of readmission during a period of time after discharge is greater.[9] 30-day readmission post discharge is usually used as an indicator of vulnerability.[2,10-12]

Readmission in patients admitted for CAP is relatively frequent (especially in the elderly and patients with multiple comorbidities), and is often associated with a worsening of a baseline disease or the appearance of a new pathology,[13] and this results in a significant clinical and economic burden for health systems.[2,14] Studies have explored the factors associated with readmission following hospitalization due to CAP, and have identified factors that improve the prognosis at discharge and are considered preventable, such as influenza and pneumococcal vaccination, the use of hospital care protocols, discharge planning and post-discharge follow-up. Adequate

1  
2  
3 discharge planning, including patient stability and destination, has been associated with  
4  
5 reduced readmission.[15-17] However, the effect of seasonal influenza and  
6  
7 pneumococcal vaccination and the adequacy of hospital care (use of clinical guidelines  
8  
9 and antibiotic plans) may be more controversial.[18-21] The initial severity of CAP,  
10  
11 worsening of comorbidities and some individual patient characteristics have been  
12  
13 described as non-preventable factors,[15,21-25] and factors such as age, sex,  
14  
15 socioeconomic status, education and some comorbidities have been independently  
16  
17 associated with a greater likelihood of readmission.[25,26]  
18

19  
20  
21 The objective of this study was to determine the risk factors associated with 30-day  
22  
23 readmission in people aged  $\geq 65$  years initially hospitalized due to CAP.  
24

## 25 26 **MATERIALS AND METHODS**

### 27 28 **Study design**

29  
30 This cross-sectional study was carried out as part of a multicenter study in 20 hospitals  
31  
32 from seven Spanish regions (Andalusia, the Basque Country, Castile and Leon,  
33  
34 Catalonia, Madrid, Navarre, and Valencian Community). Patients aged  $\geq 65$  years  
35  
36 hospitalized due to CAP in the participating hospitals during the 2013–2014 and 2014–  
37  
38 2015 influenza seasons were recruited.  
39

### 40 41 **Study population**

42  
43  
44 The Spanish health system assigns each citizen a primary healthcare centre and a  
45  
46 referral hospital to be attended. The assignation of the population to each hospital is  
47  
48 made according to geography. Consequently, if there is a readmission, it would be in the  
49  
50 same hospital. However, in an emergency, the patient may be treated in any hospital.  
51

52  
53  
54 Patients included were aged  $\geq 65$  years admitted through the emergency department to  
55  
56 any of the participating hospitals for  $\geq 24$  hours with a chest X-ray showing pulmonary  
57

1  
2  
3 infiltrate compatible with pneumonia and  $\geq 1$  of the following symptoms or signs of  
4 acute lower respiratory tract infection: cough, pleural chest pain, dyspnea, fever  $>38^{\circ}\text{C}$ ,  
5  
6 hypothermia  $< 35^{\circ}\text{C}$ , and abnormal auscultator respiratory sounds unexplained by other  
7  
8 causes.  
9

10  
11 Patients who died during the initial hospitalization and patients hospitalized for  $>30$   
12  
13 days were not included. Institutionalized patients, patients with nosocomial pneumonia  
14  
15 (onset  $\geq 48$  hours after hospital admission), patients whose main residence was not in  
16  
17 any of the seven participating regions and those who did not provide signed informed  
18  
19 consent were excluded.  
20  
21

## 22 23 **Outcomes**

24  
25 The dependent variable was 30-day readmission, defined as 'hospitalization for any  
26  
27 reason within 30 days of discharge'. Information on readmission was collected by re-  
28  
29 review of index hospital medical records up to 30 days after initial discharge.  
30  
31

32  
33 All participating hospitals had a specifically-trained team of health professionals who  
34  
35 used a structured questionnaire to obtain sociodemographic information and lifestyle  
36  
37 factors by patient interview and the review of patient's medical record to collect  
38  
39 immunization history, risk medical conditions and the CAP hospital care process.  
40  
41

42  
43 Information collected included sociodemographic variables: age, sex, marital status,  
44  
45 educational level, cohabitation; lifestyle factors: smoking status (current smoker, ex-  
46  
47 smoker, non-smoker) and high alcohol consumption ( $> 40$  g/day in men,  $> 20$  g/day in  
48  
49 women); the Barthel index,[27] was used to assess the functional capacity at hospital  
50  
51 admission (ranging from 0 - complete dependence - to 100 - complete independence).  
52  
53

54  
55 Immunization history: patients were considered vaccinated against pneumococcal  
56  
57 disease if they had receive a dose of pneumococcal vaccine in the last 5 years and  
58  
59

1  
2  
3 against seasonal influenza if they had received a dose of the influenza vaccination at  
4  
5 least 14 days before symptom onset. Risk medical conditions: comorbidities considered  
6  
7 at high or moderate risk (chronic respiratory failure, history of pneumonia during the  
8  
9 last two years, solid or hematologic neoplasm, diabetes mellitus, renal failure, chronic  
10  
11 obstructive pulmonary disease (COPD), heart failure, disabling neurological disease,  
12  
13 chronic liver disease and hemoglobinopathy or anemia) were collected from the  
14  
15 patient's medical record through chart review; comorbidities were assessed using the  
16  
17 Charlson comorbidity index,[28] which assigns a weight to each comorbid condition (0  
18  
19 No comorbidity; 1 Low comorbidity and 2 High comorbidity); Prior medical utilization  
20  
21 (number of primary care nurse visits and number of hospital visits in the last 90 days)  
22  
23 and hospital care process (severity of illness quantified in 5 risk classes using the  
24  
25 Pneumonia Severity Index (PSI) at admission,[29] length of stay (LOS) <8 days and  $\geq$ 8  
26  
27 days,[8] intensive care unit (ICU) admission, mechanical ventilation, adequacy of  
28  
29 antibiotic treatment plan (validated according to clinical guidelines) (Yes/No) and  
30  
31 discharge disposition (home without services, home with home health care or social  
32  
33 health centre).[16]  
34  
35  
36  
37

### 38 **Statistical analysis**

39  
40  
41 The Barthel index, a continuous variable, was dichotomized into 0-89 (moderate-to-  
42  
43 high degree of dependency) and  $\geq$ 90 (little or no dependency).  
44  
45

46 A bivariate analysis was conducted to compare 30-day readmission and no readmission  
47  
48 according to sociodemographic variables, lifestyle factors, the Barthel index,  
49  
50 immunization history, risk medical conditions, prior medical utilization and hospital  
51  
52 care process. Independent variables were checked for collinearity using the variance  
53  
54 inflation factor.[30]  
55  
56  
57

1  
2  
3 As Spanish regions have varying degrees of autonomy in organizing health services,  
4  
5 persons living in the same region tend to have similar access to health care. Therefore,  
6  
7 to estimate the crude odds ratio (cOR) and adjusted odds ratio (aOR), we used  
8  
9 multilevel regression models that considered the outcome variable in people from the  
10  
11 same region to obtain accurate statistical estimates of predictors of 30-day  
12  
13 readmission.[30] Covariates were introduced into the model using a backward stepwise  
14  
15 procedure, with a cut-off point of  $p < 0.2$ .

16  
17 The analysis was performed using the SPSS v.24 statistical package and Rv3.3.0  
18  
19 statistical software.  
20  
21

## 22 23 24 **Ethical approval**

25  
26 The study was approved by the Ethics Committees of the participating hospitals.  
27  
28  
29

## 30 31 **RESULTS**

32  
33 Overall, 1929 inpatients met all study eligibility criteria for CAP: 93 patients died  
34  
35 during the initial hospitalization and 80 were hospitalized for  $> 30$  days. Therefore, 1756  
36  
37 CAP cases were discharged within 30 days after the initial hospitalization: of these, 200  
38  
39 (11.39%) were readmitted within 30 days after hospital discharge (Figure 1).  
40  
41

42  
43 Figure 1. Flowchart of hospital readmissions

44  
45 The reasons for 30-day readmission were unrelated to pneumonia in 49.5% (99 cases),  
46  
47 pneumonia-related in 44.5% (89 cases) and unknown diagnosis in 6% (12 cases).  
48  
49

50  
51 The descriptive analysis and unadjusted associations of factors related to 30-day  
52  
53 readmission are shown in table 1. No differences were observed according to lifestyle  
54  
55 factors and immunization history.  
56  
57

Table 1. Distribution of 30-day readmission cases according to patient characteristics

	Readmission n=200	No Readmission n=1556	Crude OR	p value
<b>Sociodemographic</b>				
<b>Age median (range)</b>	80 (65-101)	78 (64-100)	1.02 (0.99-1.04)	0.07
<b>Age group</b>				
65-74 y.	56 (28.0%)	501 (32.2%)	1	
75-84 y.	98 (49.0%)	729 (46.9%)	1.20 (0.85-1.70)	0.31
>84 y.	46 (23.0%)	326 (20.5%)	1.26 (0.83-1.91)	0.27
<b>Sex</b>				
Female	64 (32.0%)	622 (40.0%)	1	
Male	136 (68.0%)	934 (60.0%)	1.44 (1.05 – 1.97)	0.02
<b>Educational level</b>				
No/primary education	153 (78.1%)	1118 (72.4%)	1	
Secondary or higher	43 (21.9%)	427 (27.6%)	0.75 (0.51-1.10)	0.14
<b>Marital status</b>				
Married/Cohabiting	116 (58.0%)	912 (58.6%)	1	
Single	21 (10.5%)	107 (6.9%)	1.56 (0.94-2.59)	0.09
Widowed/divorced	63 (31.5%)	536 (34.4%)	0.93 (0.67-1.29)	0.66
<b>Cohabitation</b>				
Lives alone	31 (15.5%)	289 (18.6%)	1	
Lives with cohabitant aged >15 y.	155 (77.5%)	1203 (77.4%)	1.20 (0.80 – 1.80)	0.39
Lives with cohabitant aged <15 y.	14 (7.0%)	63 (4.1%)	2.03 (1.02 – 4.04)	0.04
<b>Lifestyle factors</b>				
<b>Smoking status</b>				
Non smoker	79 (39.5%)	693 (44.5%)	1	
Smoker	16 (8.0%)	138 (8.9%)	1.04 (0.59-1.83)	0.90
Ex-smoker	105 (52.5%)	725 (46.6%)	1.28 (0.94-1.75)	0.11
<b>High alcohol consumption</b>				
No	197 (98.5%)	1524 (97.9%)	1	
Yes	3 (1.5%)	32 (2.1%)	1.38 (0.42-4.54)	0.60
<b>Prior utilization of resources</b>				
<b>N° of nurse visits in last 90d</b>				
0-2	147 (73.5%)	1182 (76.4%)	1	
≥3	53 (26.5%)	365 (23.6%)	1.17 (0.82-1.65)	0.39
<b>N° of hospital visits in last 90d</b>				
0-2	164 (82.8%)	1355 (87.6%)	1	
≥3	34 (17.2%)	192 (12.4%)	1.53 (1.02-2.31)	0.04
<b>Barthel index</b>				
Little or no dependency >90	108 (54.0%)	990 (63.6%)	1	
Moderate-to-high dependency ≤90	92 (46.0%)	566 (36.4%)	1.47 (1.08-2.01)	0.01
<b>Immunizations</b>				
<b>Influenza vaccination in any of the 3 previous seasons</b>				
No	54 (27.0%)	464 (29.8%)	1	
Yes	146 (73.0%)	1092 (70.2%)	1.16 (0.83-1.61)	0.39
<b>Pneumococcal vaccination in 5 previous years</b>				
No	161 (80.5%)	1281 (82.3%)	1	
Yes	39 (19.5%)	275 (17.7%)	1.11 (0.76-1.62)	0.58
<b>Risk medical conditions</b>				
<b>Chronic respiratory failure</b>				
No	136 (68.0%)	1269 (81.6%)	1	
Yes	64 (32.0%)	287 (18.4%)	2.08 (1.50 – 2.88)	<0.001

<b>Pneumonia during the last 2 years</b>				
No	146 (73.0%)	1267 (81.4%)	1	
Yes	54 (27.0%)	289 (18.6%)	1.65 (1.18 – 2.32)	0.004
<b>Any malignancy</b>				
No	161 (80.5%)	1271 (81.7%)	1	
Yes	39 (19.5%)	285 (18.3%)	1.08 (0.74 – 1.58)	0.67
<b>Diabetes</b>				
No	139 (69.5%)	1023 (65.7%)	1	
Yes	61 (30.5%)	533 (34.3%)	0.83 (0.60 – 1.14)	0.26
<b>Renal failure</b>				
No	151 (75.5%)	1263 (81.2%)	1	
Yes	49 (24.5%)	293 (18.8%)	1.38 (0.97 – 1.96)	0.07
<b>COPD</b>				
No	128 (64.0%)	1074 (69.0%)	1	
Yes	72 (36.0%)	482 (31.0%)	1.25 (0.92 – 1.70)	0.16
<b>Heart failure</b>				
No	128 (64.0%)	1168 (75.1%)	1	
Yes	72 (36.0%)	388 (24.9%)	1.69 (1.24 – 2.31)	0.001
<b>Chronic liver disease</b>				
No	186 (93.0%)	1504 (96.7%)	1	
Yes	14 (7.0%)	52 (3.3%)	2.13 (1.15 – 3.94)	0.01
<b>Hemoglobinopathy or anemia</b>				
No	160 (80.0%)	1324 (85.1%)	1	
Yes	40 (20.0%)	232 (14.9%)	1.40 (0.96 – 2.04)	0.08
<b>Disabling neurological disease</b>				
No	179 (89.5%)	1416 (91.0%)	1	
Yes	21 (10.5%)	140 (9.0%)	1.17 (0.72 – 1.90)	0.52
<b>Charlson Index</b>				
No comorbidity (0)	18 (9.0%)	233 (15.0%)	1	
Low comorbidity (1)	54 (27.0%)	378 (24.3%)	1.83 (1.05-3.20)	0.03
High comorbidity ( $\geq 2$ )	128 (64.0%)	945 (60.7%)	1.71 (1.02-2.86)	0.04
<b>Hospital care process</b>				
<b>ICU</b>				
No	188 (94.5%)	1499 (96.9%)	1	
Yes	11 (5.5%)	48 (3.1%)	1.93 (0.97 – 3.81)	0.06
<b>Mechanical ventilation</b>				
No	157 (78.5%)	1317 (84.9%)	1	
Yes	43 (21.5%)	235 (15.1%)	1.50 (1.03 – 2.18)	0.03
<b>Pneumonia severity index (PSI)</b>				
I-III	69 (34.7%)	645 (41.7%)	1	
IV-V	130 (65.3%)	902 (58.3%)	1.40 (1.02 – 1.92)	0.04
<b>Length of hospital stay (LOS)</b>				
<8 days	80 (40.0%)	766 (49.2%)	1	
$\geq 8$ days	120 (60.0%)	790 (50.8%)	1.45 (1.05 – 2.02)	0.02
<b>Antibiotic treatment</b>				
No	97 (50.3%)	700 (46.6%)	1	
Yes	96 (49.7%)	802 (53.4%)	1.07 (0.76 – 1.50)	0.70
<b>Discharge disposition</b>				
Home without services	185 (92.5%)	1477 (94.9%)	1	
Home with home health care	9 (4.5%)	19 (1.2%)	5.05 (1.58 – 16.15)	0.01
Social health centre	6 (3.0%)	60 (3.9%)	1.23 (0.41 – 2.92)	0.63

COPD: Chronic obstructive pulmonary disease.



Table 2. Multilevel regression analysis of factors associated with 30-day readmission.

	aOR	p value
<b>Age</b>	1.02 (0.99-1.04)	0.13
<b>Sex-Male</b>	1.39 (0.99-3.12)	0.06
<b>Cohabitation</b>		
Lives alone	1	
Lives with cohabitant aged >15 y.	1.17 (0.71-1.95)	0.54
Lives with cohabitant aged <15 y.	2.10 (1.01-4.41)	0.04
<b>Marital status</b>		
Married/Cohabiting	1	
Single	1.73 (0.96-3.11)	0.07
Widowed/Divorced	0.94 (0.61-1.44)	0.77
<b>Nº. of hospital visits ≥3</b>	1.53 (1.01-2.34)	0.04
<b>Barthel index</b>		
Moderate-to-high dependency ≤90	1.39 (0.99-1.95)	0.05
<b>Pneumonia during the last 2 years</b>	1.31 (0.91-1.88)	0.14
<b>Chronic respiratory failure</b>	1.74 (1.24-2.45)	0.001
<b>Diabetes</b>	0.74 (0.53-1.04)	0.08
<b>Heart failure</b>	1.69 (1.21-2.35)	0.002
<b>Chronic liver disease</b>	2.27 (1.20-4.31)	0.01
<b>Mechanical ventilation</b>	1.33 (0.90-1.97)	0.15
<b>Discharge disposition</b>		
Home without services	1	
Home with home health care	5.61 (1.70-18.50)	0.005
Social health centre	1.27 (0.53-3.05)	0.59

Factors independently associated with 30-day readmission in the multilevel analysis (Table 2) were living with a person aged < 15 years (aOR 2.10, 95% CI 1.01-4.41; p=0.04), > 3 hospital visits during the 90 previous days (aOR 1.53; 95% CI 1.01-2.34; p=0.04) chronic respiratory failure (aOR 1.74, 95% CI 1.24-2.45; p=0.001), heart failure (aOR 1.69, 95% CI 1.21-2.35; p=0.002), chronic liver disease (aOR 2.27, 95% CI 1.21-4.36; p=0.01) and discharge to home with home health care (aOR 5.61, 95% CI 1.70-18.50; p=0.005).

A moderate-to-high degree of dependency was tentatively associated with readmission (aOR 1.39, 95% CI 0.99-1.95; p=0.05).

1  
2  
3 No associations were observed with age, sex, pneumococcal vaccination or seasonal  
4 influenza vaccination in any of the three previous seasons, the PSI, or any variable  
5 related to the hospital care process.  
6  
7  
8  
9

## 10 **DISCUSSION**

11  
12 The overall 30-day readmission rate in our study was 11.39%. Although all  
13 participating hospitals were referral centers, readmission rates ranged between regions  
14 from 2.5% to 14%. This might be due to the differences in the hospital healthcare  
15 burden of participating hospitals and in the protocols used.  
16  
17  
18  
19  
20  
21

22 In the Pneumonia Patient Outcomes Research Team (PORT) cohort study, carried out in  
23 the United States and Canada, the readmission rate in adults was 10.1%.[31]

24  
25 Readmission rates at 30 days in people aged  $\geq 65$  years admitted for CAP vary between  
26 8% and 27%, depending on the population and country studied.[11,19,21,25,32] In  
27  
28  
29 Spain, national data show 30-days readmissions increased from 11.5% in 2004 to 13.5%  
30 in 2013 in adults admitted for CAP.[8]  
31  
32  
33  
34  
35

36 Our results show that non-preventable factors, specifically patient characteristics (living  
37 with a person aged  $< 15$  years,  $> 3$  hospital visits during the 90 previous days and some  
38 comorbidities) and one preventable factor (discharge disposition) were significantly  
39 associated with 30-day readmission. Factors such as cohabitation and the discharge  
40 disposition have been little studied and their identification provides a new perspective on  
41 the risk factors involved in 30-day readmission of these patients.  
42  
43  
44  
45  
46  
47  
48  
49

50 Calvillo-King et al. in a thorough review of studies on readmission, underlined the  
51 importance of considering social factors (sociodemographic, socioeconomic and the  
52 social environment) as elements that could influence readmission after an episode of  
53 CAP. [22] Our study evaluated sociodemographic and socioeconomic factors and the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 social environment. Although the influence of sex varies between studies and may be  
4  
5 closely related to other factors such as age, risk habits and some comorbidities, the  
6  
7 association with male sex disappeared in the final model, in contrast to the results found  
8  
9 by Neupane et al. and Bohannon et al.[19,33]  
10

11  
12 Patients living with children aged <15 years had a two-fold higher probability of  
13  
14 readmission than those living alone or with a partner. Although it is known that  
15  
16 schoolchildren may be a source of infection of the elderly in some infectious diseases,  
17  
18 we found no studies that investigated the type of cohabitation in this context, possibly  
19  
20 because one factor usually associated with readmission in people aged  $\geq 65$  years is  
21  
22 living in geriatric residences.[11] In Spain, the recommendation of vaccination of  
23  
24 persons in contact with high-risk persons, including persons aged  $\geq 65$  years with risk  
25  
26 factors has been maintained.[34] We also found no association with factors identified by  
27  
28 other authors, such as the educational level or the history of smoking or alcohol  
29  
30 use.[25,35]  
31  
32  
33

34  
35 In the studies by Neupane et al. in two Canadian cities and Adamuz et al. in a tertiary  
36  
37 hospital in Barcelona, seasonal influenza and pneumococcal vaccination were included  
38  
39 in the adjusted analysis of readmission due to CAP, but no association was  
40  
41 found.[19,23] We investigated seasonal influenza and pneumococcal vaccination in the  
42  
43 previous five years but found no association in the crude or adjusted models.  
44  
45

46  
47 In our study, 49.5% of 30-day readmissions were due to causes unrelated to CAP and  
48  
49 91% of readmitted patients presented comorbidities. Patients with chronic liver disease,  
50  
51 heart failure and respiratory failure had higher 30-day readmission rates, findings  
52  
53 consistent with other studies showing that some cardiovascular and respiratory diseases  
54  
55 play an important role in the risk of readmission in patients with CAP,[12,23-25,36] and  
56  
57  
58  
59  
60

1  
2  
3 that the reason for readmission generally differs from the initial diagnosis of CAP due,  
4  
5 in most cases, to destabilization of comorbidities.[10.23-26,37,38] Fine et al., in a  
6  
7 cohort study, found that pneumonia often occurs in patients with underlying  
8  
9 comorbidities and often results in a worsening of such underlying conditions.[31]  
10

11  
12 We found an association with prior hospital utilization in the 90 days before admission  
13  
14 for CAP, but no association with GP and primary care nurse visits. Health care in Spain  
15  
16 is free, which encourages patients to make multiple visits to primary care centers and/or  
17  
18 hospitals, ensuring patient care and follow-up. Adamuz et al. and Tang et al. found an  
19  
20 association between readmission and hospitalization in the 90 days before admission for  
21  
22 CAP.[11.23]  
23

24  
25  
26 One preventable factor that influences CAP episodes in people aged  $\geq 65$  years is the  
27  
28 quality of care received during hospitalization, while discharge planning and follow-up  
29  
30 until recovery influence patient recovery and, therefore, readmission.[16,21,23,24] We  
31  
32 found, as did Dong et al.,[16] an association with discharge to home with home health  
33  
34 care. A possible explanation might be an inadequate evaluation of the patient's stability  
35  
36 at discharge. Various authors have suggested the importance of the discharge disposition  
37  
38 in patients admitted due to other causes such as COPD or some specific  
39  
40 interventions.[39-41] However, with respect to patients with CAP, only Dong et al. and  
41  
42 the present study have found an association between the discharge disposition and  
43  
44 readmission. Other variables related to the quality of care were studied to assess these  
45  
46 aspects but no association with readmission was found.  
47  
48  
49

### 50 **Strengths and limitations**

51  
52 The main strength of the study is that all clinical information was obtained from patient  
53  
54 medical records and, therefore, was unlikely to be biased. Another strength is the cross-  
55  
56  
57

1  
2  
3 sectional design, as it is part of a multi-center study carried out in seven regions  
4  
5 representing 70% of the Spanish population.  
6

7  
8 A limitation is that it was not possible to collect patient characteristics at discharge, and  
9  
10 therefore we cannot say whether there was instability at discharge that may have caused  
11  
12 the readmission. Therefore the variable 'discharge disposition' was considered as a  
13  
14 proxy to define instability.  
15

## 16 17 **CONCLUSIONS**

18  
19 In conclusion, this study shows that 11.39% of patients aged  $\geq 65$  years hospitalized due  
20  
21 to CAP are readmitted within 30 days after an episode of CAP and that this was  
22  
23 associated with living with a cohabitant aged  $<15$  years,  $>3$  hospital visits during the 90  
24  
25 previous days, chronic respiratory failure, heart failure, chronic liver disease and  
26  
27 discharge to home with home health care services.  
28

29  
30  
31 Because social factors, in addition to post-discharge and pre-readmission clinical  
32  
33 information, may influence the prognosis, it is important that these factors continue to  
34  
35 be considered in future research.  
36

37  
38 **Author contributions:** DT, is the guarantor of this article. DT, MJP, EE, GN, ME and  
39  
40 AD, designed the research. DT, and NS conducted the statistical analyses. DT, NT and  
41  
42 AD wrote the initial draft of the manuscript, and DT, NS, NT, MJP, EE, GN, ME and  
43  
44 AD reviewed the manuscript for accuracy and scientific content. The other members of  
45  
46 the Project PI12/02079 Working Group contributed to the design of the study, patient  
47  
48 recruitment, data collection and interpretation of the results.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **A funding statement:** This study was supported by the Institute of Health Carlos III  
4 with the European Regional Development Fund (FEDER) (PI12/02079) and the Catalan  
5 Agency for the Management of Grants for University Research (AGAUR Grant number  
6 2014/ SGR 1403). The funders had no role in the study design, data collection and  
7 analysis, decision to publish, or preparation of the manuscript.  
8  
9  
10  
11  
12

13  
14 **Competing interests:** The authors declare no competing interests.  
15  
16

17 **Data Sharing Statement:** No additional data available.  
18  
19

20 **Acknowledgements:** The members of the Project PI12/02079 Working Group are, by  
21 region: Andalusia: JM Mayoral (in memoriam) (Servicio de Vigilancia de Andalucía), J  
22 Díaz-Borrego (Servicio Andaluz de Salud), A Morillo (Hospital Universitario Virgen  
23 del Rocío), MJ Pérez-Lozano (Hospital Universitario Virgen de Valme), J Gutiérrez  
24 (Hospital Universitario Puerta del Mar), M Pérez-Ruiz, MA Fernández-Sierra  
25 (Complejo Hospitalario Universitario de Granada). Castile and Leon: S Tamames  
26 (Dirección General de Salud Pública, Investigación, Desarrollo e Innovación, Junta de  
27 Castilla y León), S Rojo-Rello (Hospital Clínico Universitario de Valladolid), R Ortiz  
28 de Lejarazu (Universidad de Valladolid), MI Fernández-Natal (Complejo Asistencial  
29 Universitario de León), T Fernández-Villa (GIIGAS-Grupo de Investigación en  
30 Interacción Gen-Ambiente y Salud, Universidad de León), A Pueyo (Hospital  
31 Universitario de Burgos), V Martín (Universidad de León; CIBERESP). Catalonia: A  
32 Vilella (Hospital Clínic), M Campins, A Antón (Hospital Universitari Vall d'Hebron;  
33 Universitat Autònoma de Barcelona), G Navarro (Corporació Sanitària i Universitaria  
34 Parc Taulí), M Riera (Hospital Universitari Mútua Terrassa), E Espejo (Hospital de  
35 Terrassa), MD Mas, R Pérez (ALTHAIA, Xarxa Hospitalaria de Manresa), JA Cayla, C  
36 Rius (Agència de Salut Pública de Barcelona; CIBERESP), P Godoy (Agència de Salut  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Pública de Catalunya; Institut de Recerca Biomèdica de Lleida, Universitat de Lleida;  
4 CIBERESP), N Torner (Agència de Salut Pública de Catalunya; Universitat de  
5 Barcelona; CIBERESP), C Izquierdo, R Torra (Agència de Salut Pública de Catalunya),  
6 L Force (Hospital de Mataró), A Domínguez, N Soldevila, I Crespo (Universitat de  
7 Barcelona; CIBERESP), D Toledo (Universitat de Barcelona). Valencia Community:  
8 M. Morales-Suárez-Varela (Universidad de Valencia; CIBERESP), F. Sanz (Consorti  
9 Hospital General Universitari de Valencia). Madrid: J Astray, MF Domínguez-Berjon,  
10 MA Gutiérrez, S Jiménez, E Gil, F Martín, R Génova-Maleras (Consejería de Sanidad),  
11 MC Prados, F. Enzzine de Blas, MA Salvador, S Rodríguez, M Romero (Hospital  
12 Universitario la Paz), JC Galán, E Navas, L Rodríguez (Hospital Ramón y Cajal), CJ  
13 Álvarez, E Banderas, S Fernandez (Hospital Universitario 12 de Octubre). Basque  
14 Country: M Egurrola, MJ López de Goicoechea (Hospital de Galdakao). Navarre: J  
15 Chamorro (Complejo Hospitalario de Navarra), I Casado, J Díaz-González, J Castilla  
16 (Instituto de Salud Pública de Navarra; Instituto de Investigación Sanitaria de Navarra;  
17 CIBERESP).

## References

1. Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients. *Clin Geriatr Med* 2007;23:515-34.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 2012;67:71-9.
3. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. *Clin Microbiol Infect* 2012;18(Suppl5):7-14.

- 1  
2  
3 4. Pneumonia. In: European Lung White Book. 2nd ed. Sheffield, UK: European  
4  
5 Respiratory Society/European Lung Foundation, 2003:55-65. Available from:  
6  
7 <http://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/> (accessed  
8  
9 2017 August 14)
- 10  
11  
12 5. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in  
13  
14 the elderly: a population-based 12-year follow-up study. *Arch Intern Med*  
15  
16 1999;159:1550-55.
- 17  
18  
19 6. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired  
20  
21 pneumonia in adults in Europe: a literature review. *Thorax* 2013;68:1057-65.
- 22  
23  
24 7. Quan TP, Fawcett NJ, Wrightson JM, et al. Increasing burden of community-  
25  
26 acquired pneumonia leading to hospitalisation, 1998-2014. *Thorax* 2016;71:535-42.
- 27  
28  
29 8. de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, et al. Trends in  
30  
31 hospitalizations for community-acquired pneumonia in Spain: 2004 to 2013. *Eur J*  
32  
33 *Intern Med* 2017;40:64-71.
- 34  
35  
36 9. Marrie TJ, Haldane EV, Faulkner RS, Durant H, Kwan C. Community-acquired  
37  
38 pneumonia requiring hospitalization. Is it different in the elderly?. *J Am Geriatr Soc*  
39  
40 1985;33:671-80.
- 41  
42  
43  
44 10. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day  
45  
46 readmissions after hospitalization for heart failure, acute myocardial infarction, or  
47  
48 pneumonia. *JAMA* 2013;309:355-63.
- 49  
50  
51 11. Kahlon S, Pederson J, Majumdar SR, et al. Association between frailty and 30-day  
52  
53 outcomes after discharge from hospital. *CMAJ* 2015;187:799-804.
- 54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 12. Tang VL, Halm EA, Fine MJ, et al. Predictors of rehospitalization after admission  
4  
5 for pneumonia in the veterans affairs healthcare system. *J Hosp Med* 2014;9:379-83.  
6  
7
- 8 13. Steel K, Gertman P, Crescenzi C, Anderson J. Iatrogenic illness on a general  
9  
10 medicine service at a university hospital. *N Engl J Med* 1981;304:638-42.  
11
- 12 14. Elixhauser A, Steiner C. Readmissions to U.S. hospitals by diagnosis, 2010:  
13  
14 statistical brief #153. 2013 Apr. In: Healthcare Cost and Utilization Project (HCUP)  
15  
16 Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and  
17  
18 Quality (US); 2006 Feb-. Available from:  
19  
20 <https://www.ncbi.nlm.nih.gov/books/NBK154385/> (accessed 2017 August 16)  
21  
22
- 23 15. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on  
24  
25 hospital discharge and the risk of adverse outcomes in patients with pneumonia.  
26  
27 *Arch Intern Med* 2002;162:1278-84.  
28
- 29 16. Dong T, Cursio JF, Qadir S, et al. Discharge disposition as an independent predictor  
30  
31 of readmission among patients hospitalised for community-acquired pneumonia. *Int*  
32  
33 *J Clin Pract* 2017;71:e12935.  
34  
35
- 36 17. Auerbach AD, Kripalani S, Vasilevskis EE, et al. Preventability and causes of  
37  
38 readmissions in a national cohort of general medicine patients. *JAMA Intern Med*  
39  
40 2016;176:484-93.  
41  
42
- 43 18. Mykietiuk A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal  
44  
45 vaccination on clinical outcome of hospitalized adults with community-acquired  
46  
47 pneumococcal pneumonia. *Eur J Clin Microbiol Infect Dis* 2006;25:457-62.  
48
- 49 19. Neupane B, Walter SD, Krueger P, Marrie T, Loeb M. Predictors of in-hospital  
50  
51 mortality and re-hospitalization in older adults with community-acquired  
52  
53 pneumonia: a prospective cohort study. *BMC Geriatr* 2010;10:22.  
54  
55  
56  
57

- 1  
2  
3 20. Domínguez À, Soldevila N, Toledo D, et al. Effectiveness of 23-valent  
4 pneumococcal polysaccharide vaccination in preventing community-acquired  
5 pneumonia hospitalization and severe outcomes in the elderly in Spain. *PLoS One*  
6 2017;12:e0171943.  
7  
8  
9  
10  
11  
12 21. Lindenauer PK, Normand S-LT, Drye EE, et al. Development, validation, and  
13 results of a measure of 30-day readmission following hospitalization for pneumonia.  
14 *J Hosp Med (Online)* 2011;6:142-50.  
15  
16  
17  
18  
19 22. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of  
20 readmission or mortality in pneumonia and heart failure: systematic review. *J Gen*  
21 *Intern Med* 2013;28:269-82.  
22  
23  
24  
25  
26 23. Adamuz J, Viasus D, Campreciós-Rodríguez P, et al. A prospective cohort study of  
27 healthcare visits and rehospitalizations after discharge of patients with community-  
28 acquired pneumonia. *Respirology* 2011;16:1119-26.  
29  
30  
31  
32  
33  
34 24. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term  
35 rehospitalization following discharge of patients hospitalized with community-  
36 acquired pneumonia. *Chest* 2009;136:1079-85.  
37  
38  
39  
40  
41 25. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors  
42 for rehospitalization of patients hospitalized with community-acquired pneumonia.  
43 *Clin Infect Dis* 2008;46:550-56.  
44  
45  
46  
47  
48 26. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the  
49 Medicare fee-for-service program. *N Engl J Med* 2009;360:1418-28.  
50  
51  
52  
53 27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. *Md State Med J*  
54 1965;14:61-5.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic  
4 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*  
5 1987;40:373-83.  
6  
7  
8  
9 29. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients  
10 with community-acquired pneumonia. *N Engl J Med* 1997;336:243-50  
11  
12  
13 30. Kats MH. *Multivariable Analysis. A practical guide for clinicians and public health*  
14 *researches*. 3rd ed. New York, NY: Cambridge University Press; 2011:88-92.  
15  
16  
17 31. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients  
18 with community-acquired pneumonia: results from the Pneumonia Patient  
19 Outcomes Research Team (PORT) cohort study. *Arch Intern Med* 1999;159:970-80.  
20  
21  
22 32. Epstein AM, Jha AK, Orav EJ. The relationship between hospital admission rates  
23 and rehospitalizations. *N Engl J Med* 2011;365:2287-95.  
24  
25  
26 33. Bohannon R, Maljanian R. Hospital readmissions of elderly patients hospitalized  
27 with pneumonia. *Conn Med* 2003;67:599-603.  
28  
29  
30  
31  
32  
33 34. Ministerio de Sanidad, Servicios Sociales e Igualdad. La Gripe.  
34 <https://www.mssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm>  
35  
36 (accessed 2017 December 22)  
37  
38  
39  
40 35. El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of recurrent  
41 hospitalization for pneumonia in the elderly. *J Am Geriatr Soc* 2004;52:2010-15.  
42  
43  
44 36. Millett ER, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in  
45 the 28 days following a community-acquired pneumonia diagnosis in older adults,  
46 and their contribution to increasing hospitalisation rates over time: a cohort study.  
47 *BMJ Open* 2015;5:e008737.  
48  
49  
50  
51  
52  
53 37. O'Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization in  
54 patients hospitalized with worsening heart failure and reduced left ventricular  
55  
56  
57

- 1  
2  
3 ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure  
4 Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J* 2010;159:841-  
5 49.e1.  
6  
7  
8  
9 38. Dunlay SM, Weston SA, Killian JM, Bell MR, Jaffe AS, Roger VL. Thirty-day  
10 rehospitalizations after acute myocardial infarction: a cohort study. *Ann Intern Med*  
11 2012;157:11-8.  
12  
13  
14  
15 39. Yakubek GA, Curtis GL, Sodhi N, et al. Chronic obstructive pulmonary disease is  
16 associated with short-term complications following total hip arthroplasty. *J*  
17 *Arthroplasty* 2018; pii: S0883-5403(18)30005-6. [Epub ahead of print]  
18  
19  
20  
21 40. Cook C, Coronado RA, Bettger JP, Graham JE. The association of discharge  
22 destination with 30-day rehospitalization rates among older adults receiving lumbar  
23 spinal fusion surgery. *Musculoskelet Sci Pract* 2018;34:77-82. [Epub ahead of print]  
24  
25  
26  
27  
28 41. Dodson JA, Williams MR, Cohen DJ, Manandhar P, Vemulapalli S, Blaum C,  
29 Zhong H, Rumsfeld JS, Hochman JS. Hospital practice of direct-home discharge  
30 and 30-day readmission after transcatheter aortic valve replacement in the society of  
31 thoracic surgeons/american college of Cardiology Transcatheter Valve Therapy  
32 (STS/ACC TVT) registry. *J Am Heart Assoc* 2017; 6. pii: e006127.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flowchart of hospital readmissions

88x59mm (300 x 300 DPI)

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/ line 3-5
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5/line 21-23
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5/line 30
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5/line 30-38
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5/line 44-55 6/line 2-12
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6/line 17-56 7/line 3-23
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6/line 17-56 7/line 3-23
Bias	9	Describe any efforts to address potential sources of bias	6/line 17-56 7/line 3-23
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7/line 28-30
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7/line 33-54 8/line 3-9
		(b) Describe any methods used to examine subgroups and interactions	7/line 33-54 8/line 3-9
		(c) Explain how missing data were addressed	7/line 14-23

			8/line 1-2
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	7/line 14-23 8/line 1-2
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8/ line 22-29
		(b) Give reasons for non-participation at each stage	8/ line 22-29
		(c) Consider use of a flow diagram	8 / line 32
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8/35-45 Page 9-10
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11/line36-55
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	12/ line 13-47
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14/line 51-53 15/ line 3-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12/ line 12-55 13/ line 3-55 14/ line 6-46
Generalisability	21	Discuss the generalisability (external validity) of the study results	15/ line 20-36
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15/ line 48-57

1  
2  
3  
4 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.  
5

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
7 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
8 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only